51
|
Bono M, Pende D, Bertaina A, Moretta A, Della Chiesa M, Sivori S, Zecca M, Locatelli F, Moretta L, Bottino C, Falco M. Analysis of KIR3DP1 Polymorphism Provides Relevant Information on Centromeric KIR Gene Content. THE JOURNAL OF IMMUNOLOGY 2018; 201:1460-1467. [PMID: 30068594 DOI: 10.4049/jimmunol.1800564] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/19/2018] [Accepted: 07/04/2018] [Indexed: 11/19/2022]
Abstract
Four killer cell Ig-like receptor (KIR) genes, collectively referred to as framework genes, characterize almost all KIR haplotypes. In particular, KIR3DL3 and KIR3DL2 mark the ends of the locus, whereas KIR3DP1 and KIR2DL4 are located in the central part. A recombination hot spot, mapped between KIR3DP1 and KIR2DL4, splits the haplotypes into two regions: a centromeric (Cen) region (spanning from KIR3DL3 to KIR3DP1) and a telomeric region (from KIR2DL4 to KIR3DL2), both varying in KIR gene content. In this study, we analyzed KIR3DP1 polymorphism in a cohort of 316 healthy, unrelated individuals. To this aim, we divided KIR3DP1 alleles into two groups by the use of a sequence-specific primer- PCR approach. Our data clearly indicated that KIR3DP1 alleles present on haplotypes carrying Cen-A or Cen-B1 regions differ from those having Cen-B2 motifs. Few donors (∼3%) made exceptions, and they were all, except one, characterized by uncommon haplotypes, including either KIR deletions or KIR duplications. Consequently, as KIR2DL1 is present in Cen-A and Cen-B1 regions but absent in Cen-B2 regions, we demonstrated that KIR3DP1 polymorphism might represent a suitable marker for KIR2DL1 gene copy number analysis. Moreover, because Cen-B1 and Cen-B2 regions are characterized by different KIR3DP1 alleles, we showed that KIR3DP1 polymorphism analysis also provides information to dissect between Cen-B1/Cen-B1 and Cen-B1/Cen-B2 donors. Taken together, our data suggest that the analysis of KIR3DP1 polymorphism should be included in KIR repertoire evaluation.
Collapse
Affiliation(s)
- Maria Bono
- Dipartimento dei Laboratori di Ricerca, Istituto di Ricovero e Cura a Carattere Scientifico, Giannina Gaslini, 16147 Genoa, Italy
| | - Daniela Pende
- Dipartimento delle Terapie Oncologiche Integrate, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Policlinico San Martino, 16132 Genoa, Italy;
| | - Alice Bertaina
- Dipartimento di Oncoematologia e Terapia Cellulare e Genica, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Pediatrico Bambino Gesù, 00165 Rome, Italy
| | - Alessandro Moretta
- Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, 16132 Genoa, Italy.,Centro di Eccellenza per le Ricerche Biomediche, Università degli Studi di Genova, 16132 Genoa, Italy
| | - Mariella Della Chiesa
- Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, 16132 Genoa, Italy.,Centro di Eccellenza per le Ricerche Biomediche, Università degli Studi di Genova, 16132 Genoa, Italy
| | - Simona Sivori
- Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, 16132 Genoa, Italy.,Centro di Eccellenza per le Ricerche Biomediche, Università degli Studi di Genova, 16132 Genoa, Italy
| | - Marco Zecca
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Oncoematologia Pediatrica, 27100 Pavia, Italy; and
| | - Franco Locatelli
- Dipartimento di Oncoematologia e Terapia Cellulare e Genica, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Pediatrico Bambino Gesù, 00165 Rome, Italy
| | - Lorenzo Moretta
- Area di Ricerca Immunologica, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy
| | - Cristina Bottino
- Dipartimento dei Laboratori di Ricerca, Istituto di Ricovero e Cura a Carattere Scientifico, Giannina Gaslini, 16147 Genoa, Italy.,Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, 16132 Genoa, Italy
| | - Michela Falco
- Dipartimento dei Laboratori di Ricerca, Istituto di Ricovero e Cura a Carattere Scientifico, Giannina Gaslini, 16147 Genoa, Italy
| |
Collapse
|
52
|
Hu S, Yuan F, Feng L, Zheng F, Gong F, Huang H, Sun B. KIR2DL2/C1 is a Risk Factor for Chronic Infection and Associated with Non-response to PEG-IFN and RBV Combination Therapy in Hepatitis C Virus Genotype 1b Patients in China. Virol Sin 2018; 33:369-372. [PMID: 30039498 DOI: 10.1007/s12250-018-0042-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2018] [Accepted: 06/14/2018] [Indexed: 12/24/2022] Open
Affiliation(s)
- Song Hu
- Medical College, Jianghan University, Wuhan, 430056, China
| | - Fahu Yuan
- Medical College, Jianghan University, Wuhan, 430056, China
| | - Lingyan Feng
- Medical College, Jianghan University, Wuhan, 430056, China
| | - Fang Zheng
- Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Feili Gong
- Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Hanju Huang
- Department of Pathogen Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Binlian Sun
- Medical College, Jianghan University, Wuhan, 430056, China.
| |
Collapse
|
53
|
Heatley SL, Mullighan CG, Doherty K, Danner S, O'Connor GM, Hahn U, Szer J, Schwarer A, Bradstock K, Sullivan LC, Bardy PG, Brooks AG. Activating KIR Haplotype Influences Clinical Outcome Following HLA-Matched Sibling Hematopoietic Stem Cell Transplantation. HLA 2018; 92:74-82. [PMID: 29943500 DOI: 10.1111/tan.13327] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Revised: 06/03/2018] [Accepted: 06/22/2018] [Indexed: 01/30/2023]
Abstract
Natural killer cells are thought to influence the outcome of hematopoietic stem cell transplant (HSCT), impacting on relapse, overall survival, graft versus host disease and the control of infection, in part through the complex interplay between the large and genetically diverse killer immunoglobulin-like receptor (KIR) family and their ligands. This study examined the relationship between KIR gene content and clinical outcomes including the control of opportunistic infections such as cytomegalovirus in the setting of human leucocyte antigen (HLA)-matched sibling HSCT in an Australian cohort. The presence of the KIR B haplotype which contain more activating receptors in the donor, in particular centromeric B haplotype genes (Cen-B), was associated with improved overall survival of patients with acute myeloid leukemia (AML) undergoing sibling HSCT and receiving myeloablative conditioning. Donor Cen-B haplotype was also associated with reduced acute graft versus host disease grades II-IV whereas donor telomeric-B haplotype was associated with decreased incidence of CMV reactivation. In contrast, we were not able to demonstrate a reduced rate of relapse when the donor had KIR Cen-B, however relapse with a donor Cen-A haplotype was a competing risk factor to poor overall survival. Here we show that the presence of donor activating KIR led to improved outcome for the patient, potentially through reduced relapse rates and decreased incidence of acute GvHD translating to improved overall survival. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- S L Heatley
- University of Melbourne, Melbourne, Vic, Australia
- Australian Red Cross Blood Service, Adelaide, SA, Australia
| | - C G Mullighan
- St Jude Children's Research Hospital, Memphis, TN, USA
| | - K Doherty
- Australian Red Cross Blood Service, Adelaide, SA, Australia
| | - S Danner
- Australian Red Cross Blood Service, Adelaide, SA, Australia
- Royal Adelaide and Queen Elizabeth Hospitals, SA Pathology, Adelaide, SA, Australia
| | - G M O'Connor
- University of Melbourne, Melbourne, Vic, Australia
| | - U Hahn
- Royal Adelaide and Queen Elizabeth Hospitals, SA Pathology, Adelaide, SA, Australia
| | - J Szer
- University of Melbourne, Melbourne, Vic, Australia
- Royal Melbourne Hospital, Melbourne, Vic, Australia
| | - A Schwarer
- Alfred Hospital, Melbourne, Vic, Australia
| | | | - L C Sullivan
- University of Melbourne, Melbourne, Vic, Australia
| | - P G Bardy
- Australian Red Cross Blood Service, Adelaide, SA, Australia
- Royal Adelaide and Queen Elizabeth Hospitals, SA Pathology, Adelaide, SA, Australia
| | - A G Brooks
- University of Melbourne, Melbourne, Vic, Australia
| |
Collapse
|
54
|
Modak S, Le Luduec JB, Cheung IY, Goldman DA, Ostrovnaya I, Doubrovina E, Basu E, Kushner BH, Kramer K, Roberts SS, O'Reilly RJ, Cheung NKV, Hsu KC. Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study. Oncoimmunology 2018; 7:e1461305. [PMID: 30221057 DOI: 10.1080/2162402x.2018.1461305] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Revised: 03/27/2018] [Accepted: 03/30/2018] [Indexed: 01/30/2023] Open
Abstract
Natural killer (NK) cell-mediated antibody-dependent toxicity is a potent mechanism of action of the anti-GD2 murine monoclonal antibody 3F8 (m3F8). Killer immunoglobulin-like receptor (KIR) and HLA genotypes modulate NK activity and are key prognostic markers in m3F8-treated patients with neuroblastoma. Endogenous NK-cells are suppressed in the setting of high tumor burden and chemotherapy. Allogeneic NK-cells however, demonstrate potent anti-neuroblastoma activity. We report on the results of a phase I clinical trial of haploidentical NK-cells plus m3F8 administered to patients with high-risk neuroblastoma after conditioning chemotherapy. The primary objective was to determine the maximum tolerated NK-cell dose (MTD). Secondary objectives included assessing anti-neuroblastoma activity and its relationship to donor-recipient KIR/HLA genotypes, NK function, and donor NK chimerism. Patients received a lymphodepleting regimen prior to infusion of haploidentical CD3-CD56+ NK-cells, followed by m3F8. Overall and progression free survival (PFS) were assessed from the time of first NK-cell dose. Univariate Cox regression assessed relationship between dose and outcomes. Thirty-five patients received NK-cells at one of five dose levels ranging from <1×106 to 50×106 CD3-CD56+cells/kg. One patient experienced grade 3 hypertension and grade 4 pneumonitis. MTD was not reached. Ten patients (29%) had complete or partial response; 17 (47%) had no response; and eight (23%) had progressive disease. No relationship was found between response and KIR/HLA genotype or between response and FcγRIII receptor polymorphisms. Patients receiving >10×106 CD56+cells/kg had improved PFS (HR: 0.36, 95%CI: 0.15-0.87, p = 0.022). Patient NK-cells displayed high NKG2A expression, leading to inhibition by HLA-E-expressing neuroblastoma cells. Adoptive NK-cell therapy in combination with m3F8 is safe and has anti-neuroblastoma activity at higher cell doses.
Collapse
Affiliation(s)
- Shakeel Modak
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - Irene Y Cheung
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Debra A Goldman
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Irina Ostrovnaya
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - Ellen Basu
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Brian H Kushner
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Kim Kramer
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Stephen S Roberts
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Richard J O'Reilly
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.,Immunology Program, Sloan-Kettering Institute for Cancer Research, New York, NY
| | - Nai-Kong V Cheung
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Katharine C Hsu
- Immunology Program, Sloan-Kettering Institute for Cancer Research, New York, NY.,Weill Cornell Medical College, New York, NY.,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
55
|
Genotype B of Killer Cell Immunoglobulin-Like Receptor is Related with Gastric Cancer Lesions. Sci Rep 2018; 8:6104. [PMID: 29666399 PMCID: PMC5904182 DOI: 10.1038/s41598-018-24464-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2017] [Accepted: 03/29/2018] [Indexed: 02/06/2023] Open
Abstract
NK cells are important in innate immunity for their capacity to kill infected or cancer cells. The killer cell immunoglobulin-like receptors (KIR) are a family of polymorphic genes with inhibitory and activating functions. The main driving force for gastric cancer (GC) development is a chronic response, which causes an increase of NK cells in the gastric mucosa. The aim of this work was to study polymorphisms in KIR genes in patients with either GC or non-atrophic gastritis (NAG). We studied 242 patients (130 with NAG and 112 with GC) and contrasted with 146 asymptomatic individuals. We analyzed diversity in the content and localization of KIR genes in the different clinical groups studied. Four activating and one inhibitory genes were associated with GC: 2DS1 (OR 3.41), 2DS3 (OR 4.66), 2DS5 (OR 2.25), 3DS1 (OR 3.35) and 2DL5 (OR 3.6). The following were also found as risk factors for GC: Bx genotype (OR 4.2), Bx-Bx centromere-telomere (OR 2.55), cA01|cB03 (OR 36.39) and tB01|tB01 (OR 7.55) gene content and three B motifs (OR 10.9). Polymorphisms in KIR genes were associated with GC and suggest that mutated NK cells may contribute to GC development by increasing gastric mucosa inflammation, leading to constant tissue damage.
Collapse
|
56
|
Prognostic role of KIR genes and HLA-C after hematopoietic stem cell transplantation in a patient cohort with acute myeloid leukemia from a consanguineous community. Bone Marrow Transplant 2018; 53:1170-1179. [PMID: 29549293 DOI: 10.1038/s41409-018-0123-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2017] [Revised: 12/27/2017] [Accepted: 01/17/2018] [Indexed: 01/08/2023]
Abstract
NK cell activity is tuned by a balance of activating and inhibitory signals transmitted via their respective receptors, including killer immunoglobulin-like receptors (KIRs). The impact of NK cells on graft-versus-leukemia following hematopoietic stem cell transplantation (HSCT) is well established. These effects sometimes lead to GvHD. The link between KIR/HLA interaction and GvHD remains unclear. Herein, we studied the impact of the KIR/HLA interaction on HSCT outcomes in a longitudinal follow-up study of a highly consanguineous HLA-matched related cohort. Peripheral blood DNA was collected from HSCT donor-recipient pairs (n = 87), including 41 AML pairs. KIR and HLA were genotyped and significant results were only measured when matching KIR (donor) with HLA (recipients). GvHD was observed in 47% of patients. KIR2DL1_C2 and 2DS2_C1 (P = 0.02 and 0.04, respectively) matching was associated with an increased incidence of acute GvHD in AML donor-recipient pairs. The rate of chronic GvHD also rose in AML patients who were matched for KIR2DS1_C2 (P = 0.004) and had either KIR2DL2 or KIR2DS2 (P = 0.03). In conclusion, matching of KIR2DL1, 2DS1, and 2DS2 in donors with their HLA-C ligands in recipients is associated with increased GvHD, and holds potential for selection of HSCT donors.
Collapse
|
57
|
Parham P, Guethlein LA. Genetics of Natural Killer Cells in Human Health, Disease, and Survival. Annu Rev Immunol 2018; 36:519-548. [PMID: 29394121 DOI: 10.1146/annurev-immunol-042617-053149] [Citation(s) in RCA: 56] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Natural killer (NK) cells have vital functions in human immunity and reproduction. In the innate and adaptive immune responses to infection, particularly by viruses, NK cells respond by secreting inflammatory cytokines and killing infected cells. In reproduction, NK cells are critical for genesis of the placenta, the organ that controls the supply of oxygen and nutrients to the growing fetus. Controlling NK cell functions are interactions of HLA class I with inhibitory NK cell receptors. First evolved was the conserved interaction of HLA-E with CD94:NKG2A; later established were diverse interactions of HLA-A, -B, and -C with killer cell immunoglobulin-like receptors. Characterizing the latter interactions is rapid evolution, which distinguishes human populations and all species of higher primate. Driving this evolution are the different and competing selections imposed by pathogens on NK cell-mediated immunity and by the constraints of human reproduction on NK cell-mediated placentation. Promoting rapid evolution is independent segregation of polymorphic receptors and ligands throughout human populations.
Collapse
Affiliation(s)
- Peter Parham
- Department of Structural Biology and Department of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, California 94305, USA; ,
| | - Lisbeth A Guethlein
- Department of Structural Biology and Department of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, California 94305, USA; ,
| |
Collapse
|
58
|
Boudreau JE, Hsu KC. Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol 2018; 39:222-239. [PMID: 29397297 DOI: 10.1016/j.it.2017.12.001] [Citation(s) in RCA: 120] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Revised: 11/23/2017] [Accepted: 12/01/2017] [Indexed: 12/29/2022]
Abstract
The functional capacities of natural killer (NK) cells differ within and between individuals, reflecting considerable genetic variation. 'Licensing/arming', 'disarming', and 'tuning' are models that have been proposed to explain how interactions between MHC class I molecules and their cognate inhibitory receptors - Ly49 in mice and KIR in humans - 'educate' NK cells for variable reactivity and sensitivity to inhibition. In this review we discuss recent progress toward understanding the genetic, epigenetic, and molecular features that titrate NK effector function and inhibition, and the impact of variable NK cell education on human health and disease.
Collapse
Affiliation(s)
- Jeanette E Boudreau
- Department of Microbiology and Immunology, Dalhousie University, Halifax, Canada; Department of Pathology, Dalhousie University, Halifax, Canada.
| | - Katharine C Hsu
- Immunology Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
| |
Collapse
|
59
|
Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistance. Bone Marrow Transplant 2018; 53:949-959. [PMID: 29367714 DOI: 10.1038/s41409-017-0078-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Revised: 12/12/2017] [Accepted: 12/15/2017] [Indexed: 11/08/2022]
Abstract
The graft vs. leukemia (GvL) effect as a method of preventing relapse is well described after allogeneic hematopoietic cell transplantation (HCT), but the mechanisms to this effect and how tumor sometimes develops resistance to GvL are just beginning to be understood. This article reviews and expands upon data presented at the Third International Workshop on Biology, Prevention and Treatment of Relapse after Stem Cell Transplantation held in Hamburg, Germany, in November 2016. We first discuss in detail the role that T-cell impairment early after HCT plays in relapse by looking at data from T cell-depleted approaches as well as the clear role that early T-cell recovery has shown in improving outcomes. We then review key findings regarding the role of specific KIR donor/recipient pairings that contribute to relapse prevention after HCT for several tumor types. Finally, we discuss a unique mouse model following the development of tumor resistance to GvL. Detailed molecular characterization of events marking the development of tumor resistance to the immunotherapy of GvL may help in developing future strategies to overcome immune escape.
Collapse
|
60
|
Omosun YO, Blackstock AJ, Williamson J, van Eijk AM, Ayisi J, Otieno J, Lal RB, ter Kuile FO, Slutsker L, Shi YP. Association of maternal KIR gene content polymorphisms with reduction in perinatal transmission of HIV-1. PLoS One 2018; 13:e0191733. [PMID: 29360870 PMCID: PMC5779696 DOI: 10.1371/journal.pone.0191733] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Accepted: 01/10/2018] [Indexed: 12/29/2022] Open
Abstract
The role of killer cell immunoglobulin-like receptors (KIRs) in the transmission of HIV-1 has not been extensively studied. Here, we investigated the association of KIR gene content polymorphisms with perinatal HIV-1 transmission. The KIR gene family comprising 16 genes was genotyped in 313 HIV-1 positive Kenyan mothers paired with their infants. Gene content polymorphisms were presented as presence of individual KIR genes, haplotypes, genotypes and KIR gene concordance. The genetic data were analyzed for associations with perinatal transmission of HIV. There was no association of infant KIR genes with perinatal HIV-1 transmission. After adjustment for gravidity, viral load, and CD4 cell count, there was evidence of an association between reduction in perinatal HIV-1 transmission and the maternal individual KIR genes KIR2DL2 (adjusted OR = 0.50; 95% CI: 0.24–1.02, P = 0.06), KIR2DL5 (adjusted OR = 0.47; 95% CI: 0.23–0.95, P = 0.04) and KIR2DS5 (adjusted OR = 0.39; 95% CI: 0.18–0.80, P = 0.01). Furthermore, these maternal KIR genes were only significantly associated with reduction in perinatal HIV transmission in women with CD4 cell count ≥ 350 cells/ μl and viral load <10000 copies/ml. Concordance analysis showed that when both mother and child had KIR2DS2, there was less likelihood of perinatal HIV-1 transmission (adjusted OR = 0.44; 95% CI: 0.20–0.96, P = 0.039). In conclusion, the maternal KIR genes KIR2DL2, KIR2DL5, KIR2DS5, and KIR2DS2 were associated with reduction of HIV-1 transmission from mother to child. Furthermore, maternal immune status is an important factor in the association of KIR with perinatal HIV transmission.
Collapse
Affiliation(s)
- Yusuf O. Omosun
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
- Atlanta Research and Education Foundation, Atlanta, Georgia, United States of America
| | - Anna J. Blackstock
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
| | - John Williamson
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
| | - Anne Maria van Eijk
- Center for Global Health Research, Kenyan Medical Research Institute, Kisumu, Kenya
- Child and Reproductive Health Group, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - John Ayisi
- Center for Global Health Research, Kenyan Medical Research Institute, Kisumu, Kenya
| | - Juliana Otieno
- New Nyanza Provincial General Hospital, Ministry of Health, Kisumu, Kenya
| | - Renu B. Lal
- Division of Global HIV/AIDS, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
| | - Feiko O. ter Kuile
- Child and Reproductive Health Group, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Laurence Slutsker
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
| | - Ya Ping Shi
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
- * E-mail:
| |
Collapse
|
61
|
Baltner K, Kübler A, Pal M, Balvočiūte M, Mezger M, Handgretinger R, André MC. Expression of KIR2DS1 does not significantly contribute to NK cell cytotoxicity in HLA-C1/C2 heterozygous haplotype B donors. Int Immunol 2017; 29:423-429. [DOI: 10.1093/intimm/dxx052] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2017] [Accepted: 09/28/2017] [Indexed: 12/11/2022] Open
Affiliation(s)
- Karla Baltner
- Department of Pediatric Hematology and Oncology, University Children’s Hospital, Eberhard Karls University, 72076 Tübingen, Germany
| | - Ayline Kübler
- Department of Pediatric Hematology and Oncology, University Children’s Hospital, Eberhard Karls University, 72076 Tübingen, Germany
| | - Marina Pal
- Department of Pediatric Hematology and Oncology, University Children’s Hospital, Eberhard Karls University, 72076 Tübingen, Germany
| | - Monika Balvočiūte
- Algorithms in Bioinformatics, Faculty of Computer Science, University of Tübingen, 72076 Tübingen, Germany
| | - Markus Mezger
- Department of Pediatric Hematology and Oncology, University Children’s Hospital, Eberhard Karls University, 72076 Tübingen, Germany
| | - Rupert Handgretinger
- Department of Pediatric Hematology and Oncology, University Children’s Hospital, Eberhard Karls University, 72076 Tübingen, Germany
| | - Maya C André
- Department of Pediatric Hematology and Oncology, University Children’s Hospital, Eberhard Karls University, 72076 Tübingen, Germany
- Department of Pediatric Intensive Care, University Children’s Hospital, 4056 Basel, Switzerland
| |
Collapse
|
62
|
Gong H, Chen Y, Xu J, Xie X, Yu D, Yang B, Kuang H. The regulation of ovary and conceptus on the uterine natural killer cells during early pregnancy. Reprod Biol Endocrinol 2017; 15:73. [PMID: 28874155 PMCID: PMC5585937 DOI: 10.1186/s12958-017-0290-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Accepted: 08/25/2017] [Indexed: 01/28/2023] Open
Abstract
Uterine natural killer (uNK) cells are short-lived, terminally differentiated and the most abundant lymphocytes in the uterus which play a crucial role in the spiral arteriole modification and establishment of successful pregnancy. Dysregulation of uNK cells has been linked to gestational implications such as recurrent pregnancy loss, preeclampsia and fetal growth retardation. There is evidence showing that progesterone and estrogen can regulate the recruitment, proliferation, differentiation and function of uNK cells via direct action on intracellular nuclear receptors or through intermediary cells in the uterus during early pregnancy. As the deepening of related research in this field, the role of conceptus in such regulation has received extensive attention, it utilizes endocrine signaling (hCG), juxtacrine signaling (HLA-C, HLA-E, HLA-G) and paracrine signaling (cytokines) to facilitate the activities of uNK cells. In addition, under the influence of ovarian hormones, conceptus can increase expression of PIBF and HLA-G molecules to reduce cytotoxicity of uNK cells and promote angiogenesis. In this review, we aim to concentrate on the novel findings of ovarian hormones in the regulation of uNK cells, emphasize the regulatory role of conceptus on uNK cells and highlight the proposed issues for future research in the field.
Collapse
Affiliation(s)
- Han Gong
- 0000 0001 2182 8825grid.260463.5Department of Physiology and Jiangxi Provincial Key Laboratory of Reproductive Physiology and Pathology, Basic Medical College, Nanchang University, Nanchang, Jiangxi 330006 People’s Republic of China
- 0000 0001 2182 8825grid.260463.5Department of Clinic medicine, School of Queen Mary, Nanchang University, Nanchang, Jiangxi 330006 People’s Republic of China
| | - Yilu Chen
- 0000 0001 2182 8825grid.260463.5Department of Physiology and Jiangxi Provincial Key Laboratory of Reproductive Physiology and Pathology, Basic Medical College, Nanchang University, Nanchang, Jiangxi 330006 People’s Republic of China
| | - Jingjie Xu
- 0000 0001 2182 8825grid.260463.5Department of Physiology and Jiangxi Provincial Key Laboratory of Reproductive Physiology and Pathology, Basic Medical College, Nanchang University, Nanchang, Jiangxi 330006 People’s Republic of China
| | - Xingxing Xie
- 0000 0001 2182 8825grid.260463.5Department of Physiology and Jiangxi Provincial Key Laboratory of Reproductive Physiology and Pathology, Basic Medical College, Nanchang University, Nanchang, Jiangxi 330006 People’s Republic of China
| | - Dainan Yu
- 0000 0001 2182 8825grid.260463.5Department of Physiology and Jiangxi Provincial Key Laboratory of Reproductive Physiology and Pathology, Basic Medical College, Nanchang University, Nanchang, Jiangxi 330006 People’s Republic of China
| | - Bei Yang
- 0000 0001 2182 8825grid.260463.5Department of Physiology and Jiangxi Provincial Key Laboratory of Reproductive Physiology and Pathology, Basic Medical College, Nanchang University, Nanchang, Jiangxi 330006 People’s Republic of China
| | - Haibin Kuang
- 0000 0001 2182 8825grid.260463.5Department of Physiology and Jiangxi Provincial Key Laboratory of Reproductive Physiology and Pathology, Basic Medical College, Nanchang University, Nanchang, Jiangxi 330006 People’s Republic of China
- 0000 0001 2182 8825grid.260463.5Department of Physiology, Basic Medical College, Nanchang University, Nanchang, Jiangxi 330006 People’s Republic of China
| |
Collapse
|
63
|
Martínez-Losada C, Martín C, Gonzalez R, Manzanares B, García-Torres E, Herrera C. Patients Lacking a KIR-Ligand of HLA Group C1 or C2 Have a Better Outcome after Umbilical Cord Blood Transplantation. Front Immunol 2017; 8:810. [PMID: 28751893 PMCID: PMC5507950 DOI: 10.3389/fimmu.2017.00810] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Accepted: 06/26/2017] [Indexed: 11/24/2022] Open
Abstract
Donor natural killer (NK) cells can destroy residual leukemic cells after allogeneic hematopoietic stem cell transplantation. This effect is based on the interaction of killer-cell immunoglobulin-like receptors (KIR) of donor NK cells with ligands of the major histocompatibility complex found on the surface of the target cells. HLA-C1 subtypes provide the ligand for KIR2DL2 and KIR2DL3 and the HLA-C2 subtypes for KIR2DL1. We have studied the probability of relapse (PR) after single-unit unrelated cord blood transplantation (UCBT) in relation to the potential graft-vs.-leukemia effect mediated by NK cells present in the umbilical cord blood (UCB) by analyzing KIR-ligand and HLA-C typing of the receptor. Data from 33 consecutive patients given a single unit UCBT were included. We have considered two groups of patients based on the absence or the presence of one of the C-ligands for inhibitory KIR and the incompatibility HLA-C1/2 between UCB and patients. Group 1 (n = 21): the patient lacks a C-ligand for inhibitory KIR present in UCB NK cells, i.e., patients homozygous C1/C1 or C2/C2. Group 2 (n = 12): patients heterozygous C1/C2 in which KIR-mediated graft-vs.-leukemia effect is not expected (presence of both C ligands for inhibitory KIR in the receptor). With a median follow-up post-UCBT of 93 months, patients with absence of a C-ligand for inhibitory KIRs (Group 1) showed a lower actuarial PR than patients with both C-ligands (group 2): 21 ± 10 vs. 68 ± 18% at 2 year and 36 ± 13 vs. 84 ± 14% at 5 years (p = 0.025), respectively. In patients with acute lymphoblastic leukemia, the 2-year PR was 36 ± 21% for group 1 and 66 ± 26% for 2 (p = 0.038). Furthermore, group 1 had a lower incidence of grades II–IV acute graft-vs.-host disease (p = 0.04). In the setting of UCBT, the absence of a C-ligand (C1 or C2) of inhibitory KIR in the patient is associated with lower PR, which is probably due to the graft-vs.-host leukemia effect caused by UCB NK cells that lack a ligand for the inhibitory KIR 2DL1/2DL2/2DL3.
Collapse
Affiliation(s)
- Carmen Martínez-Losada
- Department of Hematology, Reina Sofía University Hospital/Instituto Maimónides de Investigación Biomédica (IMIBIC), University of Córdoba, Córdoba, Spain
| | - Carmen Martín
- Department of Hematology, Reina Sofía University Hospital/Instituto Maimónides de Investigación Biomédica (IMIBIC), University of Córdoba, Córdoba, Spain
| | - Rafael Gonzalez
- Department of Inmunology, Reina Sofía University Hospital, Córdoba, Spain
| | - Bárbara Manzanares
- Department of Inmunology, Reina Sofía University Hospital, Córdoba, Spain
| | - Estefania García-Torres
- Department of Hematology, Reina Sofía University Hospital/Instituto Maimónides de Investigación Biomédica (IMIBIC), University of Córdoba, Córdoba, Spain
| | - Concha Herrera
- Department of Hematology, Reina Sofía University Hospital/Instituto Maimónides de Investigación Biomédica (IMIBIC), University of Córdoba, Córdoba, Spain
| |
Collapse
|
64
|
Boudreau JE, Giglio F, Gooley TA, Stevenson PA, Le Luduec JB, Shaffer BC, Rajalingam R, Hou L, Hurley CK, Noreen H, Reed EF, Yu N, Vierra-Green C, Haagenson M, Malkki M, Petersdorf EW, Spellman S, Hsu KC. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation. J Clin Oncol 2017; 35:2268-2278. [PMID: 28520526 PMCID: PMC5501362 DOI: 10.1200/jco.2016.70.7059] [Citation(s) in RCA: 89] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose Disease relapse remains a major challenge to successful outcomes in patients who undergo allogeneic hematopoietic cell transplantation (HCT). Donor natural killer (NK) cell alloreactivity in HCT can control leukemic relapse, but capturing alloreactivity in HLA-matched HCT has been elusive. HLA expression on leukemia cells-upregulated in the post-HCT environment-signals for NK cell inhibition via inhibitory killer immunoglobulin-like (KIR) receptors and interrupts their antitumor activity. We hypothesized that varied strengths of inhibition among subtypes of the ubiquitous KIR3DL1 and its cognate ligand, HLA-B, would titrate NK reactivity against acute myelogenous leukemia (AML). Patients and Methods By using an algorithm that was based on polymorphism-driven expression levels and specificities, we predicted and tested inhibitory and cytotoxic NK potential on the basis of KIR3DL1/HLA-B subtype combinations in vitro and evaluated their impact in 1,328 patients with AML who underwent HCT from 9/10 or 10/10 HLA-matched unrelated donors. Results Segregated by KIR3DL1 subtype, NK cells demonstrated reproducible patterns of strong, weak, or noninhibition by target cells with defined HLA-B subtypes, which translated into discrete cytotoxic hierarchies against AML. In patients, KIR3DL1 and HLA-B subtype combinations that were predictive of weak inhibition or noninhibition were associated with significantly lower relapse (hazard ratio [HR], 0.72; P = .004) and overall mortality (HR, 0.84; P = .030) compared with strong inhibition combinations. The greatest effects were evident in the high-risk group of patients with all KIR ligands (relapse: HR, 0.54; P < .001; and mortality: HR, 0.74; P < .008). Beneficial effects of weak and noninhibiting KIR3DL1 and HLA-B subtype combinations were separate from and additive to the benefit of donor activating KIR2DS1. Conclusion Consideration of KIR3DL1-mediated inhibition in donor selection for HLA-matched HCT may achieve superior graft versus leukemia effects, lower risk for relapse, and an increase in survival among patients with AML.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Alleles
- Cell Line
- Child
- Child, Preschool
- Cytotoxicity Tests, Immunologic
- Female
- Genetic Variation
- Genotype
- HLA-B Antigens/genetics
- HLA-B Antigens/immunology
- Hematopoietic Stem Cell Transplantation
- Humans
- Infant
- Infant, Newborn
- Killer Cells, Natural/immunology
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/immunology
- Leukemia, Myeloid, Acute/therapy
- Male
- Middle Aged
- Receptors, KIR/genetics
- Receptors, KIR/immunology
- Receptors, KIR3DL1/genetics
- Receptors, KIR3DL1/immunology
- Recurrence
- Survival Rate
- Transplantation, Homologous
- Young Adult
Collapse
Affiliation(s)
- Jeanette E. Boudreau
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Fabio Giglio
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Ted A. Gooley
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Philip A. Stevenson
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Jean-Benoît Le Luduec
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Brian C. Shaffer
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Raja Rajalingam
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Lihua Hou
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Carolyn Katovich Hurley
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Harriet Noreen
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Elaine F. Reed
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Neng Yu
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Cynthia Vierra-Green
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Michael Haagenson
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Mari Malkki
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Effie W. Petersdorf
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Stephen Spellman
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| | - Katharine C. Hsu
- Jeanette E. Boudreau, Fabio Giglio, Jean-Benoît Le Luduec, Brian C. Shaffer, and Katharine C. Hsu, Memorial Sloan Kettering Cancer Center; Brian C. Shaffer and Katharine C. Hsu, Weill Cornell Medical College, New York, NY; Ted A. Gooley, Philip A. Stevenson, Mari Malkki, and Effie W. Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, WA; Raja Rajalingam, University of California, San Francisco, San Francisco; Elaine F. Reed, University of California, Los Angeles, Los Angeles, CA; Lihua Hou and Carolyn Katovich Hurley, Georgetown University Medical Center, Washington, DC; Harriet Noreen, University of Minnesota; Cynthia Vierra-Green, Michael Haagenson, and Stephen Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, MN; and Neng Yu, American Red Cross Blood Services, Dedham, MA
| |
Collapse
|
65
|
Zamora AE, Aguilar EG, Sungur CM, Khuat LT, Dunai C, Lochhead GR, Du J, Pomeroy C, Blazar BR, Longo DL, Venstrom JM, Baumgarth N, Murphy WJ. Licensing delineates helper and effector NK cell subsets during viral infection. JCI Insight 2017; 2:87032. [PMID: 28515356 DOI: 10.1172/jci.insight.87032] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Accepted: 04/18/2017] [Indexed: 11/17/2022] Open
Abstract
Natural killer (NK) cells can be divided into phenotypic subsets based on expression of receptors that bind self-MHC-I molecules, a concept termed licensing or education. Here we show NK cell subsets with different migratory, effector, and immunoregulatory functions in dendritic cell and antigen (ag)-specific CD8+ T cell responses during influenza and murine cytomegalovirus infections. Shortly after infection, unlicensed NK cells localized in draining lymph nodes and produced GM-CSF, which correlated with the expansion and activation of dendritic cells, and resulted in greater and sustained ag-specific T cell responses. In contrast, licensed NK cells preferentially migrated to infected tissues and produced IFN-γ. Importantly, human NK cell subsets exhibited similar phenotypic characteristics. Collectively, our studies demonstrate a critical demarcation between the functions of licensed and unlicensed NK cell subsets, with the former functioning as the classical effector subset and the latter as the stimulator of adaptive immunity helping to prime immune responses.
Collapse
Affiliation(s)
| | | | | | | | | | - G Raymond Lochhead
- Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California, USA
| | - Juan Du
- Department of Medicine, UCSF, San Francisco, California, USA
| | - Claire Pomeroy
- President of Lasker Foundation, Albert and Mary Lasker Foundation, New York City, New York, USA
| | - Bruce R Blazar
- Masonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
| | - Dan L Longo
- National Institute on Aging, NIH, Baltimore, Maryland, USA
| | | | - Nicole Baumgarth
- Center for Comparative Medicine, UC Davis, Davis, California, USA
| | - William J Murphy
- Department of Dermatology.,Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California, USA
| |
Collapse
|
66
|
Zhang HH, He J, Bao XJ, Hu X, Wang M, Zhang J, Wu XJ. [Distribution of donor-specific aKIR after unrelated allogeneic hematopoietic stem cell transplantation]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2017; 38:421-426. [PMID: 28565743 PMCID: PMC7354190 DOI: 10.3760/cma.j.issn.0253-2727.2017.05.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Subscribe] [Scholar Register] [Received: 09/20/2016] [Indexed: 11/17/2022]
Abstract
Objective: To analyze the distribution and proportion of donor-specific activated killer cell immunoglobulin like receptor (aKIR) genes and their clinical application values in unrelated allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Methods: Retrospective analyses of KIR genotyping using polymerase chain reaction with sequence specific primers (PCR-SSP) were performed in 216 pairs of donors and recipients. Results: The frequency of donor-specific KIR genes was 53.7% (116/216) in 216 patients receiving unrelated allo-HSCT, with the frequency of 78.3% (112/143) in the KIR genes mismatched group and 5.5% (4/73) in matched group. Of the 116 patients with detectable donor-specific KIR genes, 99.1% (115/116) patients had various donor-specific aKIR genes. Among 55 pairs of donors' KIR-Bx genotype and patients' KIR-AA genotype group, the most commonly observed genotypes were Bx1, Bx2, Bx3, Bx4, in which the donor-specific KIR genes were respectively KIR 3DS1, 2DL5A, 2DS5, 2DS1; KIR 3DS1, 2DL5A, 2DS3, 2DS1; KIR 2DS2, 2DL2; KIR 2DS2, 2DL2, 3DS1, 2DL5A, 2DS5, 2DS1. Of 44 pairs of donors' KIR-AA genotype and patients' KIR-Bx (AB) genotype group, 36.4% (16/44) recipients had donor-specific KIR2DS4 (FUL) gene. In 143 pairs of KIR mismatched group, the frequencies of donor-specific KIR genes were KIR2DS1 (35.7%) , KIR3DS1 (32.9%) , KIR2DS5 (29.4%) , KIR2DS4 (FUL) (25.9%) , KIR2DL2 (25.2%) , KIR2DS2 (24.5%) , KIR2DS3 (21.7%) and KIR3DL1 (8.4%) , respectively. Conclusion: The donor-specific aKIR genes mainly existed in KIR mismatched group after unrelated allo-HSCT, and the different pairs of donors' and patients' KIR genotypes led to the diverse donor-specific aKIR. But there were higher specific aKIR genes in higher frequency of KIR AA, Bx1, Bx2, Bx3, Bx4 genotypes. All these can provide the experimental basis for studying the role of the donor-specific aKIR genes on the prognosis of HSCT.
Collapse
Affiliation(s)
- H H Zhang
- Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou 215006, China
| | | | | | | | | | | | | |
Collapse
|
67
|
Rallón N, Restrepo C, Vicario JL, Del Romero J, Rodríguez C, García-Samaniego J, García M, Cabello A, Górgolas M, Benito JM. Human leucocyte antigen (HLA)-DQB1*03:02 and HLA-A*02:01 have opposite patterns in their effects on susceptibility to HIV infection. HIV Med 2017; 18:587-594. [PMID: 28218480 DOI: 10.1111/hiv.12494] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/29/2016] [Indexed: 12/31/2022]
Abstract
OBJECTIVES The objective of this study was to seek correlates of immune protection in HIV infection. We sought to elucidate the association between the presence of human leucocyte antigen (HLA) alleles, as well as killer immunoglobulin receptor (KIR) genotypes, and the susceptibility to HIV infection in a Spanish cohort of HIV-exposed seronegative (HESN) individuals. METHODS A total of 152 individuals were evaluated: 29 HESN individuals in stable heterosexual relationships with an HIV-infected partner admitting high-risk sexual intercourse for at least 12 months prior to inclusion in the study, 61 HIV-infected patients and 62 healthy controls. HLA class I and II alleles and KIR genotypes were assessed in genomic DNA from all individuals in the study by polymerase chain reaction-sequence-specific oligonucleotide (PCR-SSO) using bead array technology. RESULTS HESN individuals showed a higher prevalence of HLA-A3 (62%) and HLA-B44 (83%) supertypes compared with HIV-infected individuals (42% and 66%, respectively). Regarding specific HLA alleles, HESN individuals had a higher prevalence of HLA-A*33:01, DRB1*04 and DQB1*03:02 alleles (14%, 34% and 31%, respectively) and a lower prevalence of the HLA-A*02:01 allele (27%) than HIV-infected patients (3%, 15%, 11% and 52%, respectively; P < 0.05). Interestingly, in a multivariate analysis, only the presence of DQB1*03:02 and the absence of A*02:01 alleles were independently associated with HESN status [odds ratio (OR) 3.4 (95% confidence interval (CI) 1.1-10.5) and 0.4 (95% CI: 0.1-0.9), respectively; P < 0.05]. No KIR genotype was associated with susceptibility to HIV infection. CONCLUSIONS Our data showed that the presence of the HLA class II allele DQB1*03:02 was a correlate of immune protection against HIV infection, while the presence of the HLA class I allele A*02:01 was associated with being infected with HIV.
Collapse
Affiliation(s)
- N Rallón
- Jiménez Díaz Foundation-Health Research Institute, UAM, Madrid, Spain.,Rey Juan Carlos University Hospital, Móstoles, Spain
| | - C Restrepo
- Jiménez Díaz Foundation-Health Research Institute, UAM, Madrid, Spain.,Rey Juan Carlos University Hospital, Móstoles, Spain
| | - J L Vicario
- Histocompatibility Lab., Community Transfusion Center of Madrid, Madrid, Spain
| | | | - C Rodríguez
- Madrid Sanitary Center Sandoval, Madrid, Spain
| | - J García-Samaniego
- Carlos III-La Paz University Hospital, Madrid, Spain.,CIBERehd, Madrid, Spain
| | - M García
- Jiménez Díaz Foundation-Health Research Institute, UAM, Madrid, Spain.,Rey Juan Carlos University Hospital, Móstoles, Spain
| | - A Cabello
- Jiménez Díaz Foundation University Hospital, Madrid, Spain
| | - M Górgolas
- Jiménez Díaz Foundation University Hospital, Madrid, Spain
| | - J M Benito
- Jiménez Díaz Foundation-Health Research Institute, UAM, Madrid, Spain.,Rey Juan Carlos University Hospital, Móstoles, Spain
| |
Collapse
|
68
|
Genetic polymorphism and evolutionary differentiation of Eastern Chinese Han: a comprehensive and comparative analysis on KIRs. Sci Rep 2017; 7:42486. [PMID: 28205529 PMCID: PMC5311978 DOI: 10.1038/srep42486] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Accepted: 01/10/2017] [Indexed: 11/23/2022] Open
Abstract
Killer cell immunoglobulin-like receptor genes, namely KIRs, cluster together within the 160 kb genomic DNA region. In this study, we used PCR-SSP approach and successfully identified the genotype of 17 KIR genes in 123 independent healthy donors residing in the Jiangsu province, China. All individuals were positive at the 7 genes. The observed carrier gene frequencies (OFs) of remaining 10 KIRs ranged from 14.63% (KIR2DS3) to 95.93% (KIR3DL1). We found 27 distinct genotypes excluding KIR1D. The most frequent occurred in 63 individuals (51.22%). The linkage disequilibrium analysis signified 29 positive and 6 negative relations in 45 pairwise comparisons. To study population differentiation, we drew a Heatmap based on the data of KIRs from 59 populations and conducted Hierarchical Clustering by Euclidean distances. We next validated our results by estimating pairwise DA distances and illustrating a Neighbor-Joining tree, as well as a MDS plot covering 3 additional Chinese Han groups. The phylogenetic reconstruction and cluster analysis strongly indicated a genetically close relationship between Eastern and Jilin Hans. In conclusion, the present study provided a meritorious resource of KIR genotyping for population genetics, and could be helpful to uncover the genetic mechanism of KIRs in immune disease in the future.
Collapse
|
69
|
Malnati MS, Ugolotti E, Monti MC, Battista DD, Vanni I, Bordo D, Sironi F, Larghero P, Marco ED, Biswas P, Poli G, Vicenzi E, Riva A, Tarkowski M, Tambussi G, Nozza S, Tripodi G, Marras F, Maria AD, Pistorio A, Biassoni R. Activating Killer Immunoglobulin Receptors and HLA-C: a successful combination providing HIV-1 control. Sci Rep 2017; 7:42470. [PMID: 28211903 PMCID: PMC5304173 DOI: 10.1038/srep42470] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2016] [Accepted: 01/11/2017] [Indexed: 11/29/2022] Open
Abstract
Several studies demonstrated a relevant role of polymorphisms located within the HLA-B and -C loci and the Killer Immunoglobulin Receptors (KIRs) 3DL1 and 3DS1 in controlling HIV-1 replication. KIRs are regulatory receptors expressed at the surface of NK and CD8+ T-cells that specifically bind HLA-A and -B alleles belonging to the Bw4 supratype and all the -C alleles expressing the C1 or C2 supratype. We here disclose a novel signature associated with the Elite Controller but not with the long-term nonprogressor status concerning 2DS activating KIRs and HLA-C2 alleles insensitive to miRNA148a regulation. Overall, our findings support a crucial role of NK cells in the control of HIV-1 viremia.
Collapse
Affiliation(s)
- Mauro S. Malnati
- Unit of Human Virology, Division of Immunology, transplantation and Infectious Diseases IRCCS Ospedale San Raffaele, Milan, Italy
| | | | - Maria Cristina Monti
- Department of Public Health Unit of biostatistics and clinical epidemiology University of Pavia, Pavia Italy
| | - Davide De Battista
- Unit of Human Virology, Division of Immunology, transplantation and Infectious Diseases IRCCS Ospedale San Raffaele, Milan, Italy
| | | | | | - Francesca Sironi
- Unit of Human Virology, Division of Immunology, transplantation and Infectious Diseases IRCCS Ospedale San Raffaele, Milan, Italy
| | | | | | - Priscilla Biswas
- Unit of Human Virology, Division of Immunology, transplantation and Infectious Diseases IRCCS Ospedale San Raffaele, Milan, Italy
| | - Guido Poli
- Vita-Salute San Raffaele University, School of Medicine, Milan, Italy
| | - Elisa Vicenzi
- Unit of Viral Pathogens and Biosafety, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Agostino Riva
- Department of Clinical Sciences Chair of Infectious Diseases and Tropical Medicine University of Milan,“L. Sacco” Hospital, Milan, Italy
| | - Maciej Tarkowski
- Department of Clinical Sciences Chair of Infectious Diseases and Tropical Medicine University of Milan,“L. Sacco” Hospital, Milan, Italy
| | - Giuseppe Tambussi
- Department of Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Silvia Nozza
- Department of Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy
| | | | | | - Andrea De Maria
- IRCCS AOU San Martino-IST, Genoa, Italy
- Department of Health Science, DISSAL and Center for excellence in Biomedical Research CEBR University of Genoa, Genoa, Italy
| | | | | |
Collapse
|
70
|
Kennedy PR, Chazara O, Gardner L, Ivarsson MA, Farrell LE, Xiong S, Hiby SE, Colucci F, Sharkey AM, Moffett A. Activating KIR2DS4 Is Expressed by Uterine NK Cells and Contributes to Successful Pregnancy. THE JOURNAL OF IMMUNOLOGY 2016; 197:4292-4300. [PMID: 27815424 PMCID: PMC5114884 DOI: 10.4049/jimmunol.1601279] [Citation(s) in RCA: 65] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/22/2016] [Accepted: 09/28/2016] [Indexed: 11/19/2022]
Abstract
Tissue-specific NK cells are abundant in the pregnant uterus and interact with invading placental trophoblast cells that transform the maternal arteries to increase the fetoplacental blood supply. Genetic case-control studies have implicated killer cell Ig-like receptor (KIR) genes and their HLA ligands in pregnancy disorders characterized by failure of trophoblast arterial transformation. Activating KIR2DS1 or KIR2DS5 (when located in the centromeric region as in Africans) lower the risk of disorders when there is a fetal HLA-C allele carrying a C2 epitope. In this study, we investigated another activating KIR, KIR2DS4, and provide genetic evidence for a similar effect when carried with KIR2DS1 KIR2DS4 is expressed by ∼45% of uterine NK (uNK) cells. Similarly to KIR2DS1, triggering of KIR2DS4 on uNK cells led to secretion of GM-CSF and other chemokines, known to promote placental trophoblast invasion. Additionally, XCL1 and CCL1, identified in a screen of 120 different cytokines, were consistently secreted upon activation of KIR2DS4 on uNK cells. Inhibitory KIR2DL5A, carried in linkage disequilibrium with KIR2DS1, is expressed by peripheral blood NK cells but not by uNK cells, highlighting the unique phenotype of uNK cells compared with peripheral blood NK cells. That KIR2DS4, KIR2DS1, and some alleles of KIR2DS5 contribute to successful pregnancy suggests that activation of uNK cells by KIR binding to HLA-C is a generic mechanism promoting trophoblast invasion into the decidua.
Collapse
Affiliation(s)
- Philippa R Kennedy
- Department of Pathology, University of Cambridge, Cambridge CB2 1QP, United Kingdom; .,Centre for Trophoblast Research, University of Cambridge, Cambridge CB2 3EG, United Kingdom.,Manchester Collaborative Centre for Inflammation Research, University of Manchester, Manchester M13 9NT, United Kingdom
| | - Olympe Chazara
- Department of Pathology, University of Cambridge, Cambridge CB2 1QP, United Kingdom.,Centre for Trophoblast Research, University of Cambridge, Cambridge CB2 3EG, United Kingdom
| | - Lucy Gardner
- Department of Pathology, University of Cambridge, Cambridge CB2 1QP, United Kingdom.,Centre for Trophoblast Research, University of Cambridge, Cambridge CB2 3EG, United Kingdom
| | - Martin A Ivarsson
- Department of Pathology, University of Cambridge, Cambridge CB2 1QP, United Kingdom.,Centre for Trophoblast Research, University of Cambridge, Cambridge CB2 3EG, United Kingdom
| | - Lydia E Farrell
- Department of Pathology, University of Cambridge, Cambridge CB2 1QP, United Kingdom.,Centre for Trophoblast Research, University of Cambridge, Cambridge CB2 3EG, United Kingdom
| | - Shiqiu Xiong
- Department of Pathology, University of Cambridge, Cambridge CB2 1QP, United Kingdom.,Centre for Trophoblast Research, University of Cambridge, Cambridge CB2 3EG, United Kingdom.,Department of Molecular and Cell Biology, University of Leicester, Leicester LE1 7RH, United Kingdom; and
| | - Susan E Hiby
- Department of Pathology, University of Cambridge, Cambridge CB2 1QP, United Kingdom.,Centre for Trophoblast Research, University of Cambridge, Cambridge CB2 3EG, United Kingdom
| | - Francesco Colucci
- Centre for Trophoblast Research, University of Cambridge, Cambridge CB2 3EG, United Kingdom.,Department of Obstetrics and Gynaecology, University of Cambridge School of Clinical Medicine, National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge CB2 0SP, United Kingdom
| | - Andrew M Sharkey
- Department of Pathology, University of Cambridge, Cambridge CB2 1QP, United Kingdom.,Centre for Trophoblast Research, University of Cambridge, Cambridge CB2 3EG, United Kingdom
| | - Ashley Moffett
- Department of Pathology, University of Cambridge, Cambridge CB2 1QP, United Kingdom; .,Centre for Trophoblast Research, University of Cambridge, Cambridge CB2 3EG, United Kingdom
| |
Collapse
|
71
|
Shaffer BC, Hsu KC. How important is NK alloreactivity and KIR in allogeneic transplantation? Best Pract Res Clin Haematol 2016; 29:351-358. [PMID: 27890259 DOI: 10.1016/j.beha.2016.10.010] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Relapse of acute myelogenous leukemia (AML) after allogeneic hematopoietic cell transplantation (allo HCT) is a major cause of death in transplant recipients. Efforts to control relapse by promoting donor T-cell alloreactivity, such as withdrawal of immune suppression or donor lymphocyte infusions, are limited by the propensity to induce graft versus host disease (GVHD) and by inadequate efficacy. Therefore, options for AML patients who have relapsed AML after allo HCT are few and outcomes are poor. Similar to T-cells, natural killer (NK) cells have potent anti-leukemia effector capacity, and yet unlike T-cells, NK cells do not mediate GVHD. Furthermore, their function does not require matching of human leukocyte antigens (HLA) between donor and recipient. Maximizing donor NK alloreactivity thus holds the exciting possibility to induce the graft versus leukemia (GVL) effect without engendering GVHD. Among the array of activating and inhibitory NK cell surface receptors, the killer Ig-like receptors (KIR) play a central role in modulating NK effector function. Here we will review how KIR mediates donor alloreactivity, discuss the role of KIR gene and allele typing to optimize allo HCT donor selection, and discuss how KIR may aid adoptive NK and other cell therapies.
Collapse
Affiliation(s)
- Brian C Shaffer
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Department of Medicine, Weill Cornell Medical College, New York, NY, United States
| | - Katharine C Hsu
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Immunology Program, Sloan Kettering Institute, New York, NY, United States; Department of Medicine, Weill Cornell Medical College, New York, NY, United States.
| |
Collapse
|
72
|
Sugioka DK, Gonçalves CEI, Bicalho MDG. KIR repertory in patients with hematopoietic diseases and healthy family members. BMC HEMATOLOGY 2016; 16:25. [PMID: 27708784 PMCID: PMC5041293 DOI: 10.1186/s12878-016-0064-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/17/2016] [Accepted: 09/21/2016] [Indexed: 11/23/2022]
Abstract
Background Since the discovery of specific histocompatibility, literature has associated genes involved in the immune response, like the Human Leucocyte Antigen (HLA), with a better prognosis in transplantation. However, other non-HLA genes may also influence the immune process, such as the genes encoding the immunoglobulin-like receptors of natural killer cells (KIRs). The discovery that NK cell KIR receptors interact with conservative epitopes (C1, C2, Bw4) presented in HLA class I molecules that are genetically polymorphic, also observed in KIR genes, led to the investigation of the relevance of the KIR system to hematopoietic stem cell transplant. The cure of patients with leukemias and other hematological malignancies after bone marrow transplantation (BMT) has been attributed in part to the ability of the donor immune cells, present in the graft, to recognize and eliminate neoplastic cells of the patient. The cytotoxic activity of NK cells is mediated by the absence of HLA class I-specific ligands on the target cell surface to inhibitory KIR receptors (hypothesis of “missing-self”). Methods We analyzed, by PCR typing-SSOP technique, the presence or absence of 16 KIR genes and haplotypes of 39 patients with hematopoietic disorders and 136 healthy individuals from Paraná State. The comparisons made between the patient and control group were performed using χ2 test or Fisher exact test (bilateral p-value), as appropriated. Significance level was considered when p-value ≤ 0.05. Results Framework genes KIR3DL3, KIR3DP1, KIR2DL4 and KIR3DL2 were positive in all samples. The comparison between KIR repertoire of patients and healthy individuals revealed significant differences (p < 0.05) in inhibitors genes KIR2DL2 (p = 0.0005) and KIR2DL5 (p = 0.0067) and activating genes KIR2DS1 (p = 0.0013), KIR2DS2 (p = 0.0038), KIR2DS3 (p = 0.0153) that are more frequent in controls than in patients. The KIR2DS3 was significantly more frequent (p = 0.0031) in patients with acute myeloid leukemia (AML) when compared to patients with acute lymphoblastic leukemia (ALL). We observed a higher frequency of haplotype A (59 %) in the patients. Conclusion Our data suggests that susceptibility to leukemia can be influenced, at least, partly byKIR receptors. Electronic supplementary material The online version of this article (doi:10.1186/s12878-016-0064-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Daniele Kazue Sugioka
- Departamento de Genética, Laboratório de Imunogenética e Histocompatibilidade (LIGH), Universidade Federal do Paraná, R. Cel. Francisco H. dos Santos S/N, Centro Politécnico - Jardim das Américas, CEP 81.530.990, Curitiba, PR CP 19071 Brazil
| | - Carlos Eduardo Ibaldo Gonçalves
- Departamento de Genética, Laboratório de Imunogenética e Histocompatibilidade (LIGH), Universidade Federal do Paraná, R. Cel. Francisco H. dos Santos S/N, Centro Politécnico - Jardim das Américas, CEP 81.530.990, Curitiba, PR CP 19071 Brazil
| | - Maria da Graça Bicalho
- Departamento de Genética, Laboratório de Imunogenética e Histocompatibilidade (LIGH), Universidade Federal do Paraná, R. Cel. Francisco H. dos Santos S/N, Centro Politécnico - Jardim das Américas, CEP 81.530.990, Curitiba, PR CP 19071 Brazil
| |
Collapse
|
73
|
Siebert N, Jensen C, Troschke-Meurer S, Zumpe M, Jüttner M, Ehlert K, Kietz S, Müller I, Lode HN. Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD 2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival. Oncoimmunology 2016; 5:e1235108. [PMID: 27999754 DOI: 10.1080/2162402x.2016.1235108] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Revised: 09/07/2016] [Accepted: 09/07/2016] [Indexed: 12/11/2022] Open
Abstract
Polymorphisms in Fc-gamma-receptor (FCGR) genes as well as killer cell immunoglobulin-like receptor (KIR) and KIR ligand (KIRL) repertoires may influence antitumor effects of monoclonal antibodies (mAb). Here, we systematically analyzed high- and low-affinity FCGR2A and -3A genotypes as well as stimulating and inhibitory KIR/KIRL combinations in 53 neuroblastoma (NB) patients treated by long-term infusion (LTI) of anti-GD2 IgG1 Ab ch14.18/CHO using validated real-time PCR methods. Patients with high-affinity FCGR2A and -3A genotypes showed a higher level of Ab-dependent cell-mediated cytotoxicity (ADCC) on day 8 after the start of ch14.18/CHO and superior event-free survival (EFS) compared to patients with low FCGR genotypes. Similar observations were made for patients with stimulatory KIR/KIRL haplotype B (combination of KIR genes including activating receptor genes) compared to inhibitory haplotype A (a fixed set of genes encoding for inhibitory receptors, except 2DS4) and stronger effects were found in patients when haplotype B and high-affinity FCGRs were combined. Surprisingly, independent analysis of KIRs showed a major role of activating KIR 2DS2 for high ADCC levels and prolongation of EFS. The greatest effect was observed in 2DS2-positive patients that also had high-affinity FCGR2A and -3A genotypes. In summary, the presence of the activating KIR 2DS2 has a major effect on ADCC levels and survival in NB patients treated by LTI of ch14.18/CHO and may therefore be a useful biomarker in combination with FCGR polymorphisms for Ab-based immunotherapies.
Collapse
Affiliation(s)
- Nikolai Siebert
- Department of Pediatric Oncology and Hematology, University Medicine Greifswald , Greifswald, Germany
| | - Christian Jensen
- Department of Pediatric Oncology and Hematology, University Medicine Greifswald , Greifswald, Germany
| | - Sascha Troschke-Meurer
- Department of Pediatric Oncology and Hematology, University Medicine Greifswald , Greifswald, Germany
| | - Maxi Zumpe
- Department of Pediatric Oncology and Hematology, University Medicine Greifswald , Greifswald, Germany
| | - Madlen Jüttner
- Department of Pediatric Oncology and Hematology, University Medicine Greifswald , Greifswald, Germany
| | - Karoline Ehlert
- Department of Pediatric Oncology and Hematology, University Medicine Greifswald , Greifswald, Germany
| | - Silke Kietz
- Department of Pediatric Oncology and Hematology, University Medicine Greifswald , Greifswald, Germany
| | - Ina Müller
- Department of Pediatric Oncology and Hematology, University Medicine Greifswald , Greifswald, Germany
| | - Holger N Lode
- Department of Pediatric Oncology and Hematology, University Medicine Greifswald , Greifswald, Germany
| |
Collapse
|
74
|
Boudreau JE, Liu XR, Zhao Z, Zhang A, Shultz LD, Greiner DL, Dupont B, Hsu KC. Cell-Extrinsic MHC Class I Molecule Engagement Augments Human NK Cell Education Programmed by Cell-Intrinsic MHC Class I. Immunity 2016; 45:280-91. [PMID: 27496730 DOI: 10.1016/j.immuni.2016.07.005] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2016] [Revised: 04/23/2016] [Accepted: 05/22/2016] [Indexed: 11/19/2022]
Abstract
The effector potential of NK cells is counterbalanced by their sensitivity to inhibition by "self" MHC class I molecules in a process called "education." In humans, interactions between inhibitory killer immunoglobulin-like receptors (KIR) and human MHC (HLA) mediate NK cell education. In HLA-B(∗)27:05(+) transgenic mice and in patients undergoing HLA-mismatched hematopoietic cell transplantation (HCT), NK cells derived from human CD34(+) stem cells were educated by HLA from both donor hematopoietic cells and host stromal cells. Furthermore, mature human KIR3DL1(+) NK cells gained reactivity after adoptive transfer to HLA-B(∗)27:05(+) mice or bone marrow chimeric mice where HLA-B(∗)27:05 was restricted to either the hematopoietic or stromal compartment. Silencing of HLA in primary NK cells diminished NK cell reactivity, while acquisition of HLA from neighboring cells increased NK cell reactivity. Altogether, these findings reveal roles for cell-extrinsic HLA in driving NK cell reactivity upward, and cell-intrinsic HLA in maintaining NK cell education.
Collapse
Affiliation(s)
- Jeanette E Boudreau
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Xiao-Rong Liu
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Zeguo Zhao
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Aaron Zhang
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | | | - Dale L Greiner
- Program in Molecular Medicine Diabetes Center of Excellence, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
| | - Bo Dupont
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Katharine C Hsu
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA.
| |
Collapse
|
75
|
Wang HD, Feng ZQ, Shen CM, Guo QN, Dai PF, Zhang YD, Guo YX, Yan JW, Zhu BF, Zhang L. Study of genetic diversity of killer cell immunoglobulin-like receptor loci in the Tujia ethnic minority. Hum Immunol 2016; 77:869-875. [PMID: 27343992 DOI: 10.1016/j.humimm.2016.06.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2016] [Revised: 06/21/2016] [Accepted: 06/21/2016] [Indexed: 10/25/2022]
Abstract
The aim of this study was to analyze the genetic profiles of 14 killer cell immunoglobulin-like receptor (KIR) genes and 2 pseudogenes of 124 individuals from Tujia ethnic minority residing in Enshi Tujia and Miao autonomous prefecture of Hubei province of China and investigate the genetic relationships between the Tujia ethnic minority and other reported groups for the first time. Sequence specific primer amplification (PCR-SSP) methods were used to genotype the 14 KIR genes and 2 pseudogenes. The observed carrier frequencies (OF) and the gene frequencies (GF) of the KIR genes were measured. Neighbor-joining (N-J) tree and the principal component analysis (PCA) plot were constructed. All individuals were typed positive for the three framework loci KIR3DL3, 2DL4 and 3DL2, as well as for pseudogene KIR3DP1. The gene frequencies of the other KIR genes ranged from 9% in KIR2DS2 to 98% in KIR2DP1 and KIR3DL1. The present study of the KIR genes may be a powerful tool for enriching the Chinese ethnical gene information resources of the KIR gene pool, as well as for the anthropological research.
Collapse
Affiliation(s)
- Hong-Dan Wang
- Medical Genetic Institute of Henan Province, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou 450003, PR China; Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an 710004, PR China
| | - Zhan-Qi Feng
- Department of Urology, The First People's Hospital of Zhengzhou, Zhengzhou 450004, PR China
| | - Chun-Mei Shen
- Blood Center of Shaanxi Province, Xi'an 710061, PR China
| | - Qian-Nan Guo
- Medical Genetic Institute of Henan Province, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou 450003, PR China
| | - Peng-Fei Dai
- Department of Ophthalmology, Xi'an No. 4 Hospital, Guangren Hospital of Xi'an Jiaotong University, Xi'an 710004, PR China
| | - Yu-Dang Zhang
- Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an 710004, PR China
| | - Yu-Xin Guo
- Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an 710004, PR China
| | - Jiang-Wei Yan
- Key Laboratory of Genome Sciences, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, PR China
| | - Bo-Feng Zhu
- Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an 710004, PR China; Clinical Research Center of Shaanxi Province for Dental and Maxillofacial Diseases, College of Stomatology, Xi'an Jiaotong University, Xi'an 710004, PR China.
| | - Li Zhang
- Henan Red Cross Blood Center, Zhengzhou 450000, PR China.
| |
Collapse
|
76
|
Exploitation of natural killer cells for the treatment of acute leukemia. Blood 2016; 127:3341-9. [PMID: 27207791 DOI: 10.1182/blood-2015-12-629055] [Citation(s) in RCA: 99] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Accepted: 01/04/2016] [Indexed: 02/06/2023] Open
Abstract
Natural killer (NK) cells play an important role in surveillance and elimination of malignant cells. Their spontaneous cytotoxicity was first demonstrated in vitro against leukemia cell lines, and NK cells might play a crucial role in the therapy of leukemia. NK cell activity is controlled by an array of germ line-encoded activating and inhibitory receptors, as well as modulating coreceptors. This biologic feature can be exploited in allogeneic cell therapy, and the recognition of "missing-self" on target cells is crucial for promoting NK cell-mediated graft-versus-leukemia effects. In this regard, NK cells that express an inhibitory killer immunoglobulin-like receptor (iKIR) for which the respective major histocompatibility complex class I ligand is absent on leukemic target cells can exert alloreactivity in vitro and in vivo. Several models regarding potential donor-patient constellations have been described that have demonstrated the clinical benefit of such alloreactivity of the donor-derived NK cell system in patients with adult acute myeloid leukemia and pediatric B-cell precursor acute lymphoblastic leukemia after allogeneic stem cell transplantation. Moreover, adoptive transfer of mature allogeneic NK cells in the nontransplant or transplant setting has been shown to be safe and feasible, whereas its effectivity needs further evaluation. NK cell therapy can be further improved by optimal donor selection based on phenotypic and genotypic properties, by adoptive transfer of NK cells with ex vivo or in vivo cytokine stimulation, by the use of antibodies to induce antibody-dependent cellular cytotoxicity or to block iKIRs, or by transduction of chimeric antigen receptors.
Collapse
|
77
|
Bao X, He J, Wang M, Yuan X, Li Y, Zhang T, Li L, Chen L, Wu D. [The role of different KIR haplotypes in haplo-identical hematopoietic stem cell transplantation]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2016; 37:20-5. [PMID: 26876248 PMCID: PMC7342299 DOI: 10.3760/cma.j.issn.0253-2727.2016.01.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/17/2015] [Indexed: 11/13/2022]
Abstract
OBJECTIVE To investigate the role of different immunoglobulin- like receptor (KIR)haplotypes in haplo- identical hematopoietic stem cell transplantation (HSCT). METHOD Killer cell KIR genotyping was performed on 468 individuals from 156 unrelated families by PCR-SSP. A total of 624 KIR haplotypes from the parents were used for haplotype analysis. Ninety-two patients received haplo-identical HSCT from one of the parents. RESULTS The family study showed segregation of one A haplotype and at least 20 unique B haplotypes. The frequency of haplotype A was 72.92% (455/624). The most commonly observed haplotypes in group B were B1, B2, and B3, present at a frequency of 10.26%, 5.77%, and 4.48%, respectively. Compared to KIR gene matched donors (n=17), grafts from KIR gene mismatched donors (n= 14) had a positive effect on survival after haplo- identical HSCT for AML/MDS patients (OS: 88.2%vs 42.9%,P=0.015; RFS: 88.2%vs 35.7%,P=0.007). No effect was observed for ALL/NHL patients (OS: 76.0%vs 75.0%,P=0.727; RFS: 68.0%vs 65.0%,P=0.866). A significantly lower survival rate was observed for transplants from AA (n=52) and AB1/AB2 donors (n=15), compared to other group Bx donors (n=25) (OS: 53.3%vs 96.0%,P=0.017; RFS: 53.3%vs 92.0%,P=0.019). Meanwhile, the risk of relapse was much higher in AA group (n=52) compared to Bx group (n=40) (25.0%vs 5.0%,P=0.009). A higher risk of TRM was observed in AB1/AB2 group (P=0.012). In addition, transplant from donors carried Cen-B was associated with an increased survival compared with Cen-A homozygous donors (OS: 94.7%vs 68.5%,P=0.036; RFS: 89.5%vs 64.4%,P=0.045). CONCLUSION Overall, KIR genotyping and haplotype analyses should be useful for selection of the most optimal donors with favorable KIR gene grafts. KIR gene mismatch donors should be preferred for AML/MDS patients. Selecting donors carried Cen- B and avoiding the selection of donors of KIR genotype AA/AB1/AB2 was strongly advisable for haplo-identical HSCT.
Collapse
Affiliation(s)
- Xiaojing Bao
- Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou Institute of Blood and Marrow Transplantation, Suzhou 215006, China
| | | | | | | | | | | | | | | | | |
Collapse
|
78
|
Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime? Curr Hematol Malig Rep 2015; 10:45-58. [PMID: 25700678 PMCID: PMC4352187 DOI: 10.1007/s11899-014-0246-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Overall survival following hematopoietic cell transplantation (HCT) has improved over the past two decades through better patient selection and advances in HLA typing, supportive care, and infection prophylaxis. Nonetheless, mortality rates are still unsatisfactory and transplant-related mortality remains a major cause of death after unrelated allogeneic HCT. Since there are no known pre-HCT, non-HLA biologic predictors of survival following transplant, for over a decade, scientists have been investigating the role of non-HLA germline genetic variation in survival and treatment-related mortality after HCT. Variation in single nucleotide polymorphisms (SNPs) has the potential to impact chemotherapy, radiation, and immune responses, leading to different post-HCT survival outcomes. In this paper, we address the current knowledge of the contribution of genetic variation to survival following HCT and discuss study design and methodology for investigating HCT survival on a genomic scale.
Collapse
|
79
|
Díaz-Peña R, Vidal-Castiñeira JR, Moro-García MA, Alonso-Arias R, Castro-Santos P. Significant association of the KIR2DL3/HLA-C1 genotype with susceptibility to Crohn's disease. Hum Immunol 2015; 77:104-109. [PMID: 26542067 DOI: 10.1016/j.humimm.2015.10.020] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2015] [Revised: 09/24/2015] [Accepted: 10/31/2015] [Indexed: 10/22/2022]
Abstract
We aimed to analyze the possible association of KIR/HLA-C genotypes with the susceptibility to Crohn's disease (CD) in a Spanish population. A total of 125 patients with CD and 339 healthy controls were selected for this study. KIR and HLA-C typing were developed by sequence-specific oligonucleotide probing. We found that the centromeric A/A genotype and HLA-C1 combination was significantly increased in CD patients (P<10(-3)). The KIR2DL3/2DL3 genotype was significantly increased in CD patients (P<0.0005). Moreover, we also observed a highly significant increase of KIR2DL3-HLA-C1 homozygosis in CD patients (P<0.0005). Our results confirm the relevance of the KIR2DL2/KIR2DL3 genes and their interaction with HLA-C to CD. We show that the contribution of the KIR genes to CD susceptibility extends beyond the association with individual KIRs, with an imbalance between activating and inhibitory KIR genes seeming to influence the susceptibility to CD.
Collapse
Affiliation(s)
- Roberto Díaz-Peña
- Department of Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain; Faculty of Health Sciences, Universidad Autónoma de Chile, Talca, Chile
| | | | | | - Rebeca Alonso-Arias
- Department of Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | | |
Collapse
|
80
|
Wu X, Yao Y, Bao X, Zhou H, Tang X, Han Y, Ma X, Liu Y, Chen J, Zhou H, Jing S, Gu B, Xu Y, Sun A, He J, Wu D. KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched Transplantation in Patients with Donors with KIR Gene Haplotype A. Biol Blood Marrow Transplant 2015; 22:220-225. [PMID: 26476204 DOI: 10.1016/j.bbmt.2015.10.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Accepted: 10/04/2015] [Indexed: 10/22/2022]
Abstract
Outcomes for hematopoietic stem cell transplantation (HSCT) in various donor and recipient killer immunoglobulin-like receptor (KIR) genotypes have been studied extensively. The associations between KIR2DS4 and its variant KIR1D with outcomes of HSCT from a sibling-related HLA-matched donor with KIR haplotype A have not been explored, however. To study this, we genotyped donor-recipient pairs and divided 165 recipients of HSCT from a KIR gene haplotype A donor into 3 groups: 2DS4+/2DS4+ (2 intact KIR2DS4 alleles), 2DS4+/1D+ (heterozygous), and 1D+/1D+ (homozygous for the deletion variant KIR1D). No difference in the recovery of neutrophils and platelets among the 3 groups was observed. The cumulative incidence of grade III-IV acute graft-versus-host disease (aGVHD) within day +100 was 28.94% in the 2DS4+/2DS4+ group, 14.11% in the 2DS4+/1D+ group, and 44.44% in the 1D+/1D+ group (P = .0159). Multivariate analysis identified 1D+/1D+ as an independent risk factor for aGVHD (hazard ratio [HR], 4.221; 95% confidence interval [CI], 1.470 to 12.124; P = .007). In contrast, the cumulative incidences of chronic GVHD, 3-year cumulative relapse, and treatment-related mortality did not differ significantly among the 3 groups. The rate of cytomegalovirus (CMV) reactivation was 46.96% in the 2DS4+/2DS4+ group, 20.16% in the 2DS4+/1D+ group, and 53.25% in the 1D+/1D+ group (P = .0017). Multivariate analysis identified 2DS4+/1D+ as an independent protective factor for CMV reactivation (HR, 0.268; 95% CI, 0.125 to 0.574; P = .001). Although overall survival (OS) did not differ among the groups in the first year, the 2DS4(+)/2DS4(+) group had significantly better OS than the other groups after 1 year (P = .0361). In patients with advanced-stage disease, the 3-year probability of disease-free survival was 51.06% in the 2DS4+/2DS4+ group, 34.01% in the 2DS4+/1D+ group, and 0% in the 1D+/1D+ group (P = .0314). Collectively, our data suggest that the KIR 2DS4/1D allelic variance is associated with the outcome of sibling-related HLA-matched HSCT, and that donor subclassification of KIR 2DS4/1D alleles should be considered in this setting.
Collapse
Affiliation(s)
- Xiaojin Wu
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
| | - Yao Yao
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
| | - Xiaojing Bao
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China; HLA Laboratory, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
| | - Huifeng Zhou
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
| | - Xiaowen Tang
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
| | - Yue Han
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
| | - Xiao Ma
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
| | - Yuejun Liu
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
| | - Jia Chen
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
| | - Haixia Zhou
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
| | - Song Jing
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
| | - Bing Gu
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
| | - Yang Xu
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
| | - Aining Sun
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
| | - Jun He
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China; HLA Laboratory, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China.
| | - Depei Wu
- Department of Hematology, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China.
| |
Collapse
|
81
|
Guha P, Das A, Dutta S, Bhattacharjee S, Chaudhuri TK. Study of genetic diversity of KIR and TLR in the Rabhas, an endogamous primitive tribe of India. Hum Immunol 2015; 76:789-94. [PMID: 26429322 DOI: 10.1016/j.humimm.2015.09.024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2014] [Revised: 07/13/2015] [Accepted: 09/27/2015] [Indexed: 12/18/2022]
Abstract
The Rabha tribe is a little known small endogamous population belonging to Indo-mongoloid group of north-eastern India. We have analyzed 16 KIR and 5 TLR gene polymorphisms in the Rabha population of northern West Bengal, India for the first time. The observed frequencies of the KIR genes (except framework and pseudogene loci) ranged between 0.26 (KIR2DS3) and 0.96 (KIR2DL1). Comparisons based on KIR polymorphism have revealed that although the Rabhas are of Indian origin the presence of mongoloid component in their gene pool cannot be denied. The frequencies of the 5 TLR genes ranged between 0.90 (TLR4) and 0.46 (TLR5). TLR variations found in the Rabhas may play a synergistic role in fighting against the bacterial invasions. Our results may contribute to the understanding of (1) genetic background and extent of genetic admixture in the Rabhas, (2) population migration events and (3) KIR-disease-TLR interactions.
Collapse
Affiliation(s)
- Pokhraj Guha
- Cellular Immunology Laboratory, Department of Zoology, University of North Bengal, Raja Rammohunpur, Siliguri, West Bengal 734013, India
| | - Avishek Das
- Cellular Immunology Laboratory, Department of Zoology, University of North Bengal, Raja Rammohunpur, Siliguri, West Bengal 734013, India
| | - Somit Dutta
- Cellular Immunology Laboratory, Department of Zoology, University of North Bengal, Raja Rammohunpur, Siliguri, West Bengal 734013, India
| | - Soumen Bhattacharjee
- Cell and Molecular Biology Laboratory, Department of Zoology, University of North Bengal, Raja Rammohunpur, Siliguri, West Bengal 734013, India
| | - Tapas Kumar Chaudhuri
- Cellular Immunology Laboratory, Department of Zoology, University of North Bengal, Raja Rammohunpur, Siliguri, West Bengal 734013, India.
| |
Collapse
|
82
|
Negative Impact of Unidirectional Host-versus-Graft Killer Cell Immunoglobulin-like Receptor Ligand Mismatch on Transplantation Outcomes after Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia. Biol Blood Marrow Transplant 2015; 22:316-323. [PMID: 26415557 DOI: 10.1016/j.bbmt.2015.09.018] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2015] [Accepted: 09/21/2015] [Indexed: 12/21/2022]
Abstract
This study explored the influence of mismatched inhibitory killer cell immunoglobulin-like receptor (KIR) ligands on the outcome of haploidentical transplantation using T cell-replete, granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in adult patients with acute myeloid leukemia (AML). Three groups were examined: unidirectional graft-versus-host KIR ligand mismatched (GVH-KIR-MM; n = 33), bidirectional KIR ligand matched (KIR-M; n = 41), and unidirectional host-versus-graft KIR ligand mismatched (HVG-KIR-MM; n = 26). All recipients were treated with the same conditioning regimen (800 cGy total body irradiation, fludarabine, busulfan, and antithymocyte globulin). After a median follow-up of 26 months, the 2-year cumulative incidence of relapse was significantly higher in HVG-KIR-MM (40.3% ± 10.3%) versus others (18.9% ± 4.8%, P = .044). In the standard-risk group, the 2-year disease-free survival (DFS) was significantly lower in HVG-KIR-MM (51.8% ± 11.2%) compared with GVH-KIR-MM (88% ± 8.1%, P = .025). Multivariate analysis showed that HVG-KIR-MM was significantly associated with higher relapse (hazard ratio [HR], 10.7; P = .002) and lower DFS (HR, 3.4; P = .012). Subgroup analysis revealed increased DFS with higher doses of CD3(+)CD8(+) and CD3(-)CD56(+) grafts in GVH-KIR-MM (90.9% ± 8.7%, P = .006); there was no such effect in the other groups. Although our conclusions are limited by the absence of donor KIR genotype data, our study suggests unidirectional KIR ligand incompatibility in the host-versus-graft vector has a detrimental effect on T cell-replete haploidentical transplantation outcomes in adult patients with AML.
Collapse
|
83
|
Manser AR, Weinhold S, Uhrberg M. Human KIR repertoires: shaped by genetic diversity and evolution. Immunol Rev 2015; 267:178-96. [DOI: 10.1111/imr.12316] [Citation(s) in RCA: 75] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Angela R. Manser
- Institute for Transplantation Diagnostics and Cell Therapeutics; Heinrich-Heine University Düsseldorf; Medical Faculty; Düsseldorf Germany
| | - Sandra Weinhold
- Institute for Transplantation Diagnostics and Cell Therapeutics; Heinrich-Heine University Düsseldorf; Medical Faculty; Düsseldorf Germany
| | - Markus Uhrberg
- Institute for Transplantation Diagnostics and Cell Therapeutics; Heinrich-Heine University Düsseldorf; Medical Faculty; Düsseldorf Germany
| |
Collapse
|
84
|
Augusto DG, O’Connor GM, Lobo-Alves SC, Bass S, Martin MP, Carrington M, McVicar DW, Petzl-Erler ML. Pemphigus is associated with KIR3DL2 expression levels and provides evidence that KIR3DL2 may bind HLA-A3 and A11 in vivo. Eur J Immunol 2015; 45:2052-60. [PMID: 25867094 PMCID: PMC4530613 DOI: 10.1002/eji.201445324] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2014] [Revised: 03/03/2015] [Accepted: 04/09/2015] [Indexed: 12/18/2022]
Abstract
Although HLA-A3 and A11 have been reported to be ligands for KIR3DL2, evidence for any in vivo relevance of this interaction is still missing. To explore the functional importance of KIR3DL2 allelic variation, we analyzed the autoimmune disease pemphigus foliaceus, previously associated (lower risk) with activating KIR genes. KIR3DL2*001 was increased in patients (odds ratio (OR) = 2.04; p = 0.007). The risk was higher for the presence of both KIR3DL2*001 and HLA-A3 or A11 (OR = 3.76, p = 0.013), providing the first evidence that HLA-A3 and A11 may interact with KIR3DL2 in vivo. The nonsynonymous single nucleotide polymorphism 1190T (rs3745902) was associated with protection (OR = 0.52, p = 0.018). This SNP results in a threonine-to-methionine substitution. Individuals who have methionine in this position exhibit a lower percentage of KIR3DL2-positive natural killer (NK) cells and also lower intensity of KIR3DL2 on expressing natural killer cells; additionally, we show that the expression of KIR3DL2 is independent of other killer cell immunoglobulin-like receptors. Pemphigus foliaceus is a very unique complex disease strongly associated with immune-related genes. It is the only autoimmune disease known to be endemic, showing a strong correlation with environmental factors. Our data demonstrate that this relatively unknown autoimmune disease may facilitate understanding of the molecular mechanisms of KIR3DL2 ligand recognition.
Collapse
Affiliation(s)
- Danillo G. Augusto
- Departamento de Genética, Universidade Federal do Paraná, Curitiba, PR, 81531-980, Brazil
- Ragon Institute of MGH, MIT and Harvard, Boston, MA, 02139, USA
- Leidos Biomedical Research, Cancer and Inflammation Program, Laboratory for Experimental Immunology, Frederick National Laboratory for Cancer Research, Frederick, MD 21702
| | - Geraldine M. O’Connor
- Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702, USA
| | - Sara C. Lobo-Alves
- Departamento de Genética, Universidade Federal do Paraná, Curitiba, PR, 81531-980, Brazil
| | - Sara Bass
- Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702, USA
| | - Maureen P. Martin
- Leidos Biomedical Research, Cancer and Inflammation Program, Laboratory for Experimental Immunology, Frederick National Laboratory for Cancer Research, Frederick, MD 21702
| | - Mary Carrington
- Ragon Institute of MGH, MIT and Harvard, Boston, MA, 02139, USA
- Leidos Biomedical Research, Cancer and Inflammation Program, Laboratory for Experimental Immunology, Frederick National Laboratory for Cancer Research, Frederick, MD 21702
| | - Daniel W. McVicar
- Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702, USA
| | | |
Collapse
|
85
|
Mulrooney TJ, Zhang AC, Goldgur Y, Boudreau JE, Hsu KC. KIR3DS1-Specific D0 Domain Polymorphisms Disrupt KIR3DL1 Surface Expression and HLA Binding. THE JOURNAL OF IMMUNOLOGY 2015; 195:1242-50. [PMID: 26109640 DOI: 10.4049/jimmunol.1500243] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Accepted: 05/26/2015] [Indexed: 11/19/2022]
Abstract
KIR3DL1 is a polymorphic inhibitory receptor that modulates NK cell activity through interacting with HLA-A and HLA-B alleles that carry the Bw4 epitope. Amino acid polymorphisms throughout KIR3DL1 impact receptor surface expression and affinity for HLA. KIR3DL1/S1 encodes inhibitory and activating alleles, but despite high homology with KIR3DL1, the activating receptor KIR3DS1 does not bind the same ligand. Allele KIR3DL1*009 resulted from a gene recombination event between the inhibitory receptor allele KIR3DL1*001 and the activating receptor allele KIR3DS1*013. This study analyzed the functional impact of KIR3DS1-specific polymorphisms on KIR3DL1*009 surface expression, binding to HLA, and functional capacity. Flow-cytometric analysis of primary human NK cells as well as transfected HEK293T cells shows that KIR3DL1*009 is expressed at a significantly lower surface density compared with KIR3DL1*001. Using recombinant proteins of KIR3DL1*001, KIR3DL1*009, and KIR3DS1*013 to analyze binding to HLA, we found that although KIR3DL1*009 displayed some evidence of binding to HLA compared with KIR3DS1*013, the binding was minimal compared with KIR3DL1*001 and KIR3DL1*005. Mutagenesis of polymorphic sites revealed that the surface phenotype and reduced binding of KIR3DL1*009 are caused by the combined amino acid polymorphisms at positions 58 and 92 within the D0 extracellular domain. Resulting from these effects, KIR3DL1*009(+) NK cells exhibited significantly less inhibition by HLA-Bw4(+) target cells compared with KIR3DL1*001(+) NK cells. The data from this study contribute novel insight into how KIR3DS1-specific polymorphisms in the extracellular region impact KIR3DL1 surface expression, ligand binding, and inhibitory function.
Collapse
Affiliation(s)
| | - Aaron C Zhang
- Immunology Program, Sloan Kettering Institute, New York, NY 10065
| | - Yehuda Goldgur
- Department of Structural Biology, Sloan Kettering Institute, New York, NY 10065
| | | | - Katharine C Hsu
- Immunology Program, Sloan Kettering Institute, New York, NY 10065; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065; and Weill Cornell Medical College, Cornell University, New York, NY 10065
| |
Collapse
|
86
|
Braun K, Wolfe J, Kiazyk S, Kaushal Sharma M. Evaluation of host genetics on outcome of tuberculosis infection due to differences in killer immunoglobulin-like receptor gene frequencies and haplotypes. BMC Genet 2015; 16:63. [PMID: 26077983 PMCID: PMC4467048 DOI: 10.1186/s12863-015-0224-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2015] [Accepted: 06/01/2015] [Indexed: 11/10/2022] Open
Abstract
Background Outcome of Mycobacterium tuberculosis (Mtb) infection is affected by virulence of the infecting strain of Mtb, host environment, co-morbidities, and the genetic composition of the host, specifically the presence or absence of genes involved in immune responses/regulation. It is hypothesized that specific killer immunoglobulin-like receptor (KIR) genes may be associated with Mtb infection and clinical outcome. This cross-sectional study examined the KIR gene frequencies, profiles, and haplotypes of individuals with active tuberculosis, latent tuberculosis infection, compared to TB and HIV negative healthy controls. Results Analysis of KIR gene frequencies revealed differences among disease status groups, suggesting that enrichment or depletion of specific KIR genes may direct the disease outcome. Mtb infected individuals were more likely to have a centromeric-AA haplotype compared to controls. Conclusion The differences in KIR gene frequencies and haplotypes may result in differential cytokine expression, contributing to different disease outcomes, and suggest a genetic influence on Mtb susceptibility and pathogenesis.
Collapse
Affiliation(s)
- Kali Braun
- Department of Medical Microbiology, University of Manitoba, 543-745 Bannatyne Avenue, Winnipeg, R3E 0 J9, MB, Canada.
| | - Joyce Wolfe
- National Reference Centre for Mycobacteriology, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, R3E 3R2, MB, Canada.
| | - Sandra Kiazyk
- Department of Medical Microbiology, University of Manitoba, 543-745 Bannatyne Avenue, Winnipeg, R3E 0 J9, MB, Canada. .,National Reference Centre for Mycobacteriology, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, R3E 3R2, MB, Canada.
| | - Meenu Kaushal Sharma
- Department of Medical Microbiology, University of Manitoba, 543-745 Bannatyne Avenue, Winnipeg, R3E 0 J9, MB, Canada. .,National Reference Centre for Mycobacteriology, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, R3E 3R2, MB, Canada.
| |
Collapse
|
87
|
Bani M, Seket J, Kaabi H, Cherif G, Chaabane M, Bellali H, Hmida S. Killer cell immunoglobulin-like receptor (KIR) locus profiles in the Tunisian population. Hum Immunol 2015; 76:355-61. [DOI: 10.1016/j.humimm.2015.03.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2013] [Revised: 02/17/2015] [Accepted: 03/11/2015] [Indexed: 10/23/2022]
|
88
|
Resistance to hepatitis C virus: potential genetic and immunological determinants. THE LANCET. INFECTIOUS DISEASES 2015; 15:451-60. [PMID: 25703062 DOI: 10.1016/s1473-3099(14)70965-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Studies of individuals who were highly exposed but seronegative (HESN) for HIV infection led to the discovery that homozygosity for the Δ32 deletion mutation in the CCR5 gene prevents viral entry into target cells, and is associated with resistance to infection. Additionally, evidence for protective immunity has been noted in some HESN groups, such as sex workers in The Gambia. Population studies of individuals at high risk for hepatitis C virus infection suggest that an HESN phenotype exists. The body of evidence, which suggests that protective immunity allows clearance of hepatitis C virus without seroconversion is growing. Furthermore, proof-of-principle evidence from in-vitro studies shows that genetic polymorphisms can confer resistance to establishment of infection. This Review discusses the possibility that genetic mutations confer resistance against hepatitis C virus, and also explores evidence for protective immunity, including via genetically programmed variations in host responses. The data generally strengthens the notion that investigations of naturally arising polymorphisms within the hepatitis C virus interactome, and genetic association studies of well characterised HESN individuals, could identify potential targets for vaccine design and inform novel therapies.
Collapse
|
89
|
He Y, Tao S, Ying Y, He J, Zhu F, Lv H. Investigation of killer cell immunoglobulin-like receptors KIR2DL2 and KIR2DL3 diversity and identification of ten novel KIR2DL3 alleles in the Chinese Han population. Scand J Immunol 2015; 81:265-71. [PMID: 25651940 DOI: 10.1111/sji.12277] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2014] [Accepted: 01/22/2015] [Indexed: 11/30/2022]
Abstract
KIR2DL2 and KIR2DL3 are important inhibitory receptors that recognize a subset of HLA-C allelic products carrying Ser77 and Asn80. In this study, we have determined KIR2DL2 and KIR2DL3 diversity in the Chinese Han population by a PCR sequence-based typing. Based on sequencing, the coding regions of 166 Chinese Han individuals, seven new polymorphic sites (238G>A, 405G>A, 476A>G, 550G>A, 608G>A, 789T>C, 947T>C) were found. KIR2DL2*00301, *00101, KIR2DL3*00101,*00201,*013, *015 and ten new KIR2DL3 variants (KIR2DL3*00105, 00106, 00107, 00108, 019, 020, 021, 022, 023 and 024) were identified, of which KIR2DL3*00101 was the most frequent allele. Compared with the sequences of KIR2DL3*00101, all sequences of 2DL3*00105, 2DL3*00106, 2DL3*00107 and 2DL3*00108 had one nucleotide substitution(789T>C, 261C>T, 489G>A and 405G>A),but none resulted in amino acid change. An A>G substitution was observed in nucleotide position 476 in 2DL3*019, 608 G>A in 2DL3*020, 824T>C in 2DL3*021 and 238 G>A in 2DL3*023. In addition, 2DL3*022 probably arose from 2DL3*00201 with a nucleotide substitution G>A at 550. There were more HLA-C1 positive individuals than HLA-C2. In conclusion, the data of allelic polymorphism for KIR2DL2 and KIR2DL3 were obtained in the Chinese Han population and ten novel KIR2DL3 alleles were identified.
Collapse
Affiliation(s)
- Y He
- Blood Center of Zhejiang Province, Hangzhou, Zhejiang, China ; Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, Zhejiang, China
| | | | | | | | | | | |
Collapse
|
90
|
Cheung NKV, Ostrovnaya I, Kuk D, Cheung IY. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy. J Clin Oncol 2015; 33:755-63. [PMID: 25559819 DOI: 10.1200/jco.2014.57.6777] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
PURPOSE Immunotherapy is a standard of care for children with high-risk neuroblastoma, where bone marrow (BM) is the predominant metastatic site. Early response markers of minimal residual disease (MRD) in the BM that are also predictive of survival could help individualize patient therapies. PATIENTS AND METHODS After achieving first remission (n = 163), primary refractory disease (n = 102), or second remission (n = 95), children with stage 4 neuroblastoma received anti-GD2 3F8 antibody immunotherapy. BM MRD before 3F8 treatment and after cycle 2 (postMRD) was measured using a four-marker panel (B4GALNT1, PHOX2B, CCND1, and ISL1) by quantitative reverse transcription polymerase chain reaction. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Prognostic variables were tested in both univariable and multivariable analyses, and MRD markers were further assessed individually and in combination as binary composite (postMRD: 0 and 1) and as equal sum (postMRDSum: 0 to 4) using the Cox regression models, and their predictive accuracy was determined by the concordance index. RESULTS When BM was evaluated after cycle 2, individual markers were highly predictive of PFS and OS. The prediction accuracy improved when they were combined in postMRDSum. A multivariable model taking into account all the variables significant in the univariable analyses identified postMRDSum to be independently predictive of PFS and OS. When the model for OS also included missing killer immunoglobulin-like receptor ligand, human antimouse antibody response, and the enrollment disease status, the concordance index was 0.704. CONCLUSION BM MRD after two cycles of immunotherapy was confirmed as an early response marker and a consistent independent predictor of survival.
Collapse
Affiliation(s)
| | - Irina Ostrovnaya
- All authors: Memorial Sloan Kettering Cancer Center, New York, NY
| | - Deborah Kuk
- All authors: Memorial Sloan Kettering Cancer Center, New York, NY
| | - Irene Y Cheung
- All authors: Memorial Sloan Kettering Cancer Center, New York, NY.
| |
Collapse
|
91
|
Venstrom JM, Dupont B, Hsu KC, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E. Donor activating KIR2DS1 in leukemia. N Engl J Med 2014; 371:2042. [PMID: 25409391 DOI: 10.1056/nejmc1411443] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
92
|
KIR and HLA genotypes have no identifiable role in single-unit dominance following double-unit umbilical cord blood transplantation. Bone Marrow Transplant 2014; 50:150-2. [PMID: 25310305 PMCID: PMC4286450 DOI: 10.1038/bmt.2014.218] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
93
|
Falco M, Moretta L, Moretta A, Bottino C. KIR and KIR ligand polymorphism: a new area for clinical applications? ACTA ACUST UNITED AC 2014; 82:363-73. [PMID: 24498992 DOI: 10.1111/tan.12262] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Killer immunoglobulin-like receptors (KIRs) play an essential role in the regulation of natural killer (NK) activity, allowing NK cells to sense and respond to human leukocyte antigen (HLA) class I downregulation, an important hallmark for viral infections and tumor transformation. KIR and HLA genes are located on different chromosomes and KIR/HLA class I interaction represents an example of genetic epistasis in which the presence of receptor/ligand pairs is necessary for the induction of functional activity, while the presence of one in the absence of the other is not sufficient to influence NK cell function. Due to the high degree of HLA class I and KIR gene variability, KIR/KIR-ligand (KIR-L) interactions are extraordinarily diverse. KIR polymorphism arises from both haplotypic and allelic variations and was shaped by natural selection. KIR variability affects NK cell education influencing the KIR repertoire, KIR expression, the strength of KIR/KIR-L interactions and the capability to deliver signals. Moreover, it may influence NK cell function during infections, autoimmune diseases, pregnancy and allogeneic transplantation. This review summarizes the genetic and functional features of KIR/KIR-L interactions and gives an overview of their potential relevance in clinical studies.
Collapse
Affiliation(s)
- M Falco
- Istituto Giannina Gaslini, Genoa, Italy
| | | | | | | |
Collapse
|
94
|
Guha P, Bhattacharjee S, Chaudhuri TK. Diversity of killer cell immunoglobulin-like receptor genes in the Bengali population of northern West Bengal, India. Scand J Immunol 2014; 80:441-51. [PMID: 25205074 DOI: 10.1111/sji.12239] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2014] [Accepted: 08/06/2014] [Indexed: 11/26/2022]
Abstract
The Indian Subcontinent exhibits extensive diversity in its culture, religion, ethnicity and linguistic heritage, which symbolizes extensive genetic variations within the populations. The highly polymorphic Killer cell Immunoglobulin-like Receptor (KIR) family plays an important role in tracing genetic differentiation in human population. In this study, we aimed to analyse the KIR gene polymorphism in the Bengali population of northern West Bengal, India. To our knowledge, this is the first report on the KIR gene polymorphism in the Bengalis of West Bengal, India. Herein, we have studied the distribution of 14 KIR genes (KIR3DL1-3DL3, KIR2DL1-2DL5, KIR2DS1-2DS5 AND KIR3DS1) and two pseudogenes (KIR3DP1 and 2DP1) in the Bengalis. Apart from the framework genes (KIR2DL4, 3DL2, 3DL3 and 3DP1), which are present in all the individuals, the gene frequencies of other KIR genes varied between 0.34 and 0.88. Moreover, upon comparing the KIR polymorphism of the Bengalis with the available published data of other world populations, it has been found that the Indo-European-speaking Bengalis from the region share both Dravidian and Indo-Aryan gene pool with considerable influences of mongoloid and European descents. Furthermore, evidences from previously published data on human leucocyte antigen and Y-chromosome haplogroup diversity support the view. Our results will help to understand the genetic background of the Bengali population, in illustrating the population migration events in the eastern and north-eastern part of India, in explaining the extensive genetic admixture amongst the different linguistic groups of the region and also in KIR-related disease researches.
Collapse
Affiliation(s)
- P Guha
- Cellular Immunology Laboratory, Department of Zoology, University of North Bengal, Siliguri, India
| | | | | |
Collapse
|
95
|
Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung SH, Zhou L, Hsu K, Czuczman MS, Cheson B, Kaplan L, Lanier LL, Venstrom JM. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2014; 2:878-89. [PMID: 24958280 PMCID: PMC4264658 DOI: 10.1158/2326-6066.cir-13-0158] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Natural killer (NK) cells contribute to clinical responses in patients treated with rituximab, but the rules determining NK-cell responsiveness to mAb therapies are poorly defined. A deeper understanding of the mechanisms responsible for antibody-dependent cellular cytotoxicity (ADCC) could yield useful biomarkers for predicting clinical responses in patients. Unlicensed NK cells, defined as NK cells lacking expression of an inhibitory KIR for self-HLA class I ligands, are hyporesponsive in steady state, but are potent effectors in inflammatory conditions. We hypothesized that antitumor antibodies such as rituximab can overcome NK-cell dependence on licensing, making unlicensed NK cells important for clinical responses. Here, we examined the influences of variations in KIR and HLA class I alleles on in vitro responses to rituximab. We tested the clinical significance in a cohort of patients with follicular lymphoma treated with rituximab-containing mAb combinations, and show that rituximab triggers responses from all NK-cell populations regardless of licensing. Neither IL2 nor accessory cells are required for activating unlicensed NK cells, but both can augment rituximab-mediated ADCC. Moreover, in 101 patients with follicular lymphoma treated with rituximab-containing mAb combinations, a "missing ligand" genotype (predictive of unlicensed NK cells) is associated with a higher rate of progression-free survival. Our data suggest that the clinical efficacy of rituximab may be driven, in part, by its ability to broaden the NK-cell repertoire to include previously hyporesponsive, unlicensed NK cells. A "missing ligand" KIR and HLA class I genotype may be predictive of this benefit and useful for personalizing treatment decisions in lymphomas and other tumors.
Collapse
Affiliation(s)
- Juan Du
- Department of Medicine, University of California, San Francisco, San Francisco, California
| | - Sandra Lopez-Verges
- Department of Microbiology and Immunology and the Cancer Research Institute, University of California, San Francisco, San Francisco, California
| | - Brandelyn N Pitcher
- Alliance Statistics and Data Center, Duke University Medical Center, Durham, North Carolina
| | - Jeffrey Johnson
- Alliance Statistics and Data Center, Duke University Medical Center, Durham, North Carolina
| | - Sin-Ho Jung
- Alliance Statistics and Data Center, Duke University Medical Center, Durham, North Carolina
| | - Lili Zhou
- Department of Medicine, University of California, San Francisco, San Francisco, California
| | - Katharine Hsu
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Myron S Czuczman
- Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York
| | - Bruce Cheson
- Department of Medicine, Georgetown University, Washington, District of Columbia
| | - Lawrence Kaplan
- Department of Medicine, University of California, San Francisco, San Francisco, California
| | - Lewis L Lanier
- Department of Microbiology and Immunology and the Cancer Research Institute, University of California, San Francisco, San Francisco, California
| | - Jeffrey M Venstrom
- Department of Medicine, University of California, San Francisco, San Francisco, California.
| |
Collapse
|
96
|
Impola U, Turpeinen H, Alakulppi N, Linjama T, Volin L, Niittyvuopio R, Partanen J, Koskela S. Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients. Front Immunol 2014; 5:405. [PMID: 25202311 PMCID: PMC4142321 DOI: 10.3389/fimmu.2014.00405] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2014] [Accepted: 08/07/2014] [Indexed: 11/17/2022] Open
Abstract
Successful allogeneic hematopoietic stem cell transplantation (HSCT) depends not only on good HLA match but also on T-cell mediated graft-versus-leukemia (GvL) effect. Natural killer (NK) cells are able to kill malignant cells by receiving activation signal from the killer-cell immunoglobulin-like receptors (KIR) recognizing HLA molecules on a cancer cell. It has been recently reported that the risk of relapse in allogeneic hematopoietic stem cell transplantation (HSCT) is reduced in acute myeloid leukemia (AML) patients whose donors have several activating KIR genes or KIR B-motifs in unrelated donor setting, obviously due to enhanced GvL effect by NK cells. We studied the effect on relapse rate of donor KIR haplotypes in the HLA-identical adult sibling HSCT, done in a single center, in Helsinki University Central Hospital, Helsinki, Finland. Altogether, 134 patients with 6 different diagnoses were identified. Their donors were KIR genotyped using the Luminex and the SSP techniques. The clinical endpoint, that is, occurrence of relapse, was compared with the presence or absence of single KIR genes. Also, time from transplantation to relapse was analyzed. The patients with AML whose donors have KIR2DL2 or KIR2DS2 had statistically significantly longer relapse-free survival (P = 0.015). Our data support previous reports that donors with KIR B-haplotype defining genes have a lower occurrence of relapse in HSCT of AML patients. Determination of donor KIR haplotypes could be a useful addition for a risk assessment of HSCT especially in AML patients.
Collapse
Affiliation(s)
- Ulla Impola
- FRC Blood Service, Research and Development , Helsinki , Finland
| | - Hannu Turpeinen
- Institute of Biosciences and Medical Technology (BioMediTech), University of Tampere , Tampere , Finland
| | - Noora Alakulppi
- FRC Blood Service, Research and Development , Helsinki , Finland
| | - Tiina Linjama
- FRC Blood Service, Research and Development , Helsinki , Finland
| | - Liisa Volin
- Division of Hematology, Helsinki University Central Hospital , Helsinki , Finland
| | - Riitta Niittyvuopio
- Division of Hematology, Helsinki University Central Hospital , Helsinki , Finland
| | - Jukka Partanen
- FRC Blood Service, Research and Development , Helsinki , Finland
| | - Satu Koskela
- FRC Blood Service, Research and Development , Helsinki , Finland
| |
Collapse
|
97
|
Bao X, Wang M, Zhou H, Wu X, Yang L, Xu C, Yuan X, Zhang J, Li L, Wu D, He J. Characterization of Killer cell immunoglobulin-like receptor (KIR) genotypes and haplotypes in Chinese Han population. ACTA ACUST UNITED AC 2014; 82:327-37. [PMID: 24131019 DOI: 10.1111/tan.12211] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2013] [Revised: 07/30/2013] [Accepted: 09/07/2013] [Indexed: 11/29/2022]
Abstract
We performed Killer cell immunoglobulin-like receptor (KIR) genotyping on 1271 individuals of Chinese Han origin including 102 families and 965 unrelated individuals. The families (with one child and both parents) were subjected for haplotype analysis. Forty-one different genotypes were identified. The frequencies of the KIR genotypes found in the family panel were confirmed by those found in the unrelated panel. The family study showed segregation of one A haplotype and at least 15 unique B haplotypes. The most commonly observed haplotypes in group B were B1, B2, and B3, present at a frequency of 10.05%, 6.62%, and 4.90%, respectively. On the basis of the combination of KIR genes, six centromeric and seven telomeric gene motifs have been identified. Motif cB02 was the most frequent haplotype B specific centromeric segment while tB01 was the most frequent haplotype B specific telomeric segment. The distinct distribution of KIR haplotypes in each population may reflect the history of directional and balancing selection of different races. The gene combinations of group A and B1/B2/B3 haplotype were the most frequent genotypes named as Bx1, Bx2, and Bx3, present at a frequency of 13.72%, 7.35%, and 4.41% in the family panel, and at a frequency of 15.86%, 10.15%, and 5.80% in the unrelated panel, respectively. Overall, this study showed the diversity of KIR haplotypes and genotypes in Chinese Han population and developed a criterion for distinguish KIR haplotypes/genotypes for the population. KIR genotyping and haplotype analysis should be useful for selection of the most optimum donor grafts with favorable KIR gene content for transplants.
Collapse
Affiliation(s)
- X Bao
- Department of HLA Laboratory, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, 215007, Jiangsu, P.R. China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
98
|
Vidal-Castiñeira JR, López-Vázquez A, Martínez-Borra J, Martínez-Camblor P, Prieto J, López-Rodríguez R, Sanz-Cameno P, de la Vega J, Rodrigo L, Pérez-López R, Pérez-Álvarez R, López-Larrea C. Diversity of killer cell immunoglobulin-like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcome. PLoS One 2014; 9:e99426. [PMID: 24927414 PMCID: PMC4057177 DOI: 10.1371/journal.pone.0099426] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Accepted: 05/14/2014] [Indexed: 01/22/2023] Open
Abstract
The aim of this study was to analyse the distribution of KIR haplotypes and the KIR2DL2/3 alleles in chronic HCV-infected patients in order to establish the influence on the response to pegylated interferon plus ribavirin classical treatment. The alleles study of previously associated KIR2DL2/3 showed that KIR2DL2*001 was more frequent in non-SVR (NSVR) (42.2% vs. 27.5%, p<0.05) and KIR2DL3*001 was associated with sustained viral response (SVR) (41.6% vs. 61.2%, p<0.005). The KIR2DL3*001-HLA-C1 association was also significant (24.5% vs. 45.7%, p<0.001). From the frequencies of KIR obtained, 35 genotypes were assigned on the basis of previous studies. The centromeric A/A genotype was more frequent in SVR (44.1% vs. 34.5%, p<0.005) and the centromeric B/B genotype was found to be significantly more frequent in NSVR (20.9% vs. 11.2%, p<0.001). The logic regression model showed the importance of KIR genes in predicting the response to combined treatment, since the positive predictive value (PPV) was improved (from 55.9% to 75.3%) when the analysis of KIR was included in addition to the IFNL3 rs12979860 polymorphism. The study of KIR receptors may be a powerful tool for predicting the combined treatment response in patients with chronic HCV infection in association with the determination of IFNL3 polymorphism.
Collapse
Affiliation(s)
| | | | | | | | - Jesús Prieto
- Liver Unit and Division of Hepatology and Gene Therapy, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain
| | - Rosario López-Rodríguez
- Liver Unit, Gastroenterology Service, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid and CIBERehd, Instituto de Salud Carlos III, Madrid, Spain
| | - Paloma Sanz-Cameno
- Liver Unit, Gastroenterology Service, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid and CIBERehd, Instituto de Salud Carlos III, Madrid, Spain
| | - Juan de la Vega
- Gastroenterology Service, Hospital San Agustín, Avilés, Spain
| | - Luis Rodrigo
- Gastroenterology Service, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Rosa Pérez-López
- Gastroenterology Service, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Ramón Pérez-Álvarez
- Gastroenterology Service, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Carlos López-Larrea
- Immunology Service, Hospital Universitario Central de Asturias, Oviedo, Spain
- Fundación Renal Iñigo Álvarez de Toledo, Madrid, Spain
| |
Collapse
|
99
|
Boudreau JE, Le Luduec JB, Hsu KC. Development of a novel multiplex PCR assay to detect functional subtypes of KIR3DL1 alleles. PLoS One 2014; 9:e99543. [PMID: 24919192 PMCID: PMC4053526 DOI: 10.1371/journal.pone.0099543] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Accepted: 05/16/2014] [Indexed: 11/18/2022] Open
Abstract
Among NK cell receptor-ligand partnerships, KIR3DL1 and HLA-Bw4 demonstrate the greatest diversity; permutations of their allelic combinations titrate NK reactivity. Balancing selection has maintained distinct subtypes of KIR3DL1 alleles in global populations, implying that each may provide unique fitness advantages and variably influence disease processes. Though approaches exist for determining HLA-B allotypes, practical methods for identifying KIR3DL1 alleles are lacking. We have developed a PCR-based approach that identifies functional subtypes of KIR3DL1 alleles; it is suitable for research and may have clinical application. Six allele subsets were identified based on expression characteristics of the eleven most common KIR3DL1 alleles represented in reported populations. The remaining 62 low-frequency alleles were distributed into these groups based on sequence homology to coding regions. Subtype-specific SNPs were found in exons 3, 4, and 7, and used as priming sites for five multiplex PCR reactions. Genomic DNA derived from 175 unrelated donors and 52 related individuals from 6 families demonstrated >99.5% concordance between sequence-based typing and our novel approach. Finally, PCR-based typing accurately predicted NK phenotypes obtained by flow cytometry after staining with DX9 and Z27 monoclonal antibodies. This novel approach facilitates high-throughput analysis of KIR3DL1 allotypes to enable a broader understanding of KIR3DL1 and HLA-Bw4 interaction in health and disease.
Collapse
Affiliation(s)
- Jeanette E. Boudreau
- Immunology Program, Sloan-Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
| | - Jean-Benoît Le Luduec
- Immunology Program, Sloan-Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
| | - Katharine C. Hsu
- Immunology Program, Sloan-Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
- Weill Medical College, Cornell University, New York, New York, United States of America
- * E-mail:
| |
Collapse
|
100
|
Giebel S, Boratyn-Nowicka A, Karabon L, Jedynak A, Pamula-Pilat J, Tecza K, Kula D, Kowal M, Frydecka I, Grzybowska E. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with epithelial ovarian cancer. Hum Immunol 2014; 75:508-13. [DOI: 10.1016/j.humimm.2014.04.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2013] [Revised: 01/19/2014] [Accepted: 04/05/2014] [Indexed: 10/25/2022]
|